A vac o pa n ( C C X 1 6 8)   Pr ot oc ol C L [ADDRESS_788282] u d y Title:  A Ra n d o mize d, D o u ble- Bli n d, Place b o- C o ntr olle d, Parallel 
Gr o u p, P hase 2 St u d y t o E val uate t he Saf et y a n d Efficac y of A vac o pa n i n S u bjects wit h M o derate t o Se ver e Hi dra de nitis S u p p urati va 
Pr ot oc ol N u m ber:  C L [ADDRESS_788283]: A vac o pa n  (f or merl y C C X 1 6 8) 
I n dic ati o n: Treat me nt of s u bjects wit h Hi dra de nitis S u p p urati va 
S p o ns or:  C he m o Ce ntr y x, I n c.  
De vel o p me nt P h ase:  [ADDRESS_788284] a C T n u m ber  2 0 1 8- 0 0 2 3 5 1- 1 5 
S p o ns or's Res p o nsi b le 
Me dic al Officer:   
C he m o Ce ntr y x, I n c.  
 
S p o ns or Si g n at or y:  
Ori gi n al : 
A me n d me nt 1. 0 : 
A me n d me nt 2. 0 : [ADDRESS_788285] u d y will be c o n d u cte d acc or di n g t o t he pri n ci ples of G o o d Cli nical Practice as 
descri be d i n I nter nati o nal C o nfere nce o n H ar m o nizati o n g ui deli nes, i ncl u di n g t he arc hi vi n g of esse ntial d oc u me nts. P P D
P P DP P D
Avacopan (CCX168)  Protocol CL016_168 
31 July 2019 Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 2 of 87 INVESTIGATOR SIGNATORY PAGE  
Protocol Number:  CL0 16_168 
Protocol Title:  A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 
Study to Evaluate the Safety and Effi cacy of Avacopan in Subjects with Moderate to Severe 
Hidradenitis Suppurativa 
I agree:  
•To assume responsibility for the proper conduct of the study at this site.
•To conduct the study in compliance with this protocol, any future amendments, and
with any oth er study conduct procedures provided by [CONTACT_596792], Inc.
•Not to implement any deviations from or changes to the protocol without agreement
from the Sponsor and prior review and written approval from the Institutional Review
Board (IRB)/Ethics Committee ( EC), except where necessary to eliminate an
immediate hazard  to the subject s, or for administrative aspects of the study (where
permitted by [CONTACT_72016]).
•That I am thoroughly familiar with the appropriate use of the investigatio nal drug(s),
as described in this protocol, and any other information provided by [CONTACT_596793], but not limited to the following: the current version of the Investigator’sBrochure prepared by [CONTACT_596792], Inc. and approved product label, if appl icable.
•That I am aware of and will comply with current International Conference on
Harmonisation ( ICH)/Food and Drug Administration  (FDA ) good clinical practices
(GCP) guidelines and all regulatory requirements.
•To ensure that all persons assisting me with the study are adequately informed about
the investigational drug(s) and their study-related duties and function as described inthe protocol.
__________________________________ ___________________ 
Principal Investigator   [CONTACT_1782]  
__________________________________ Printed Name  
[CONTACT_2761]*_____________________________________________________________ 
____________________________________________________________________ Phone Number* ___________________________________________ 
* If the address or phone number needs to be changed during the course of the study, this will
be done by [CONTACT_737], with written notification to the Sponsor, and will not require (a)protocol amendment(s).
A vac o pa n ( C C X 1 6 8)  Pr ot oc ol C L 0 1 6 _ 1 6 8 
3 1 J ul y 2 0 1 9 A me n d me nt 2. 0 
C he m o Ce ntr y x, I n c.  C O N FI D E N TI A L  Pa ge 3  of 8 7  S P O N S O R C O N T A C T I N F O R M A TI O N  
Pr ot oc ol N u m ber:  C L 0 1 6 _ 1 6 8 
Pr ot oc ol Title:  A R a n d o mize d, D o u ble- Bli n d, Place b o- C o ntr olle d, Par allel Gr o u p, P hase [ADDRESS_788286] u d y t o E v al uate t he Saf et y a n d Efficac y of A vac o pa n i n S u bjects wit h M o derate t o Se vere Hi dra de nitis S u p p urati va 
Me dical Offi cer   
Vice Presi de nt Cli nical De vel o p me nt  a n d Tra nsl ati o nal Me dici ne 
C he m o Ce ntr y x, I n c.  
 
 
 
 
Cli nical O perati o ns 
Ma na g er   
C he m o Ce ntr y x, I n c.  
 
 
 
 P P D
P P D
P P D
P P D
A v a c o p a n ( C C X 1 6 8) 
3 1 J ul y 2 0 1 9 
S P O N S O R SI G N A T U R E F O R A P P R O V A L 
P r ot o c ol N u m b e r: C L 0 1 6 1 6 8 Pr ot o c ol C L 0 1 6 1 6 8 
A m e n d m e nt 2. 0 
P r ot o c ol Title: A R a n d o mi z e d, D o u bl e- Bli n d, Pl a c e b o- C o ntr oll e d, P ar all el Gr o u p, P h as e [ADDRESS_788287] a d e nitis S u p p ur ati v a 
Vi c e Pr esi d e nt, Cli ni c al D e v el o p m e nt 
a n d Tr a nsl ati o n al M e di ci n e D at e 
C h e m o C e ntr y x, I nc. C O N FI D E N TI A L P a g e 4 of 8 7 P P D P P D
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 5 of 87 PROTOCOL AMENDMENT 2.0: SUMMARY OF CHANGES  
1. The protocol Title Page  was updated with the new amendment number and date. 
2. Collection of the Dermatology Life Quality Index (DLQI)  and the Work Productivity and 
Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP)  scores  were 
updated throughout the document. 
3. Period [ADDRESS_788288] been updated to  include the term “hypertrophic” where appropriate throughout the 
document. 
5. SYNOPSIS - Secondary and Other Objectives  and Section 2.[ADDRESS_788289] been added. 
8. SYNOPSIS - Study Interventions/Methodology and Section 4.[ADDRESS_788290] been updated to include details on discontinuation of study medication due to 
inadequate or worsening response during the 24- week active treatment period.  
9. SYNOPSIS - Study Interventions/Methodology  and Section 3.[ADDRESS_788291] been updated to state that not more than 20% of enrolled subjects will be 
on allowed concomitant antibiotic  therapy . 
10. SYNOPSIS - Criteria for Inclusion and  Section 4.[ADDRESS_788292] 5 inflammatory nodules and abscesses at 
Screening in Inclusion #5 and to clarify contraception  methods in Inclusion #7. 
11. SYNOPSIS - Criteria for Exclusion and  Section 4.[ADDRESS_788293] on HS in Exclusion #9. 
12. STUDY SCHEMA has been u pdated to clarify the two treatment periods.  
13. TIME AND EVENTS TABLE has been updated:  
a. To add a urine pregnancy test for women of childbearing potential on Day 1; 
b.To add collection of DLQI and WPAI:SHP score s (in Patient-Reported Outcomes) and 
Health -Economic Information;  
c. To clarify the collection of AEs at Screening;  
d.To clarify  the maximum number of days allowed to exceed the Screening period; 
e. To update PK blood sample collection for timepoints up to 3 hours following dosing; 
f. To add study procedures to Week 24 and 32 visits; 
g.To add exploratory biomarker plasma sample collection at Day 1, Week 12, and Week 36 or Early Termination visits; 
Avacopan (CCX168)   Protocol CL016_168 
[ADDRESS_788294] on HS including systemic antibiotics , antiseptics, 
analgesics, wound care, and lesion intervention methods. 
16. Section  6 STUDY PROCEDURES has been updated to harmonize study procedures with Time 
and Events Table in Sections  6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 6.10, 6.11, 6.12, 6.13 
and 6.14. 
17. Section  7.1.1 Location and Extent of Hidradenitis Suppurativa Assessment has been updated to 
specify that the same Investigator should assess the lesions at each visit to assure consistency. 
18. Section  7.1.7 Health -Economic Information  has been added . 
19. Section  [IP_ADDRESS] Adverse Events of Special Interest (AE SI) has been added. 
20. Section  7.2.[ADDRESS_788295] been 
added. 
29. Section  8.8.12 C ovariates and  Subgroups has been updated to include new variables for the 
analysis of the efficacy endpoints. 
30. Section  8.9 Interim Analyses has been updated  to include a potential futility analysis .
A vac o pa n ( C C X 1 6 8)   Pr ot oc ol C L [ADDRESS_788296] u d y Desi g n  ........................................................................ 3 4  
3. 5.  Rati o nale f or D ose Sel ecti o n  ...................................................................................... 3 5  
4.  S T U D Y P O P U L A TI O N  ............................................................................................. 3 6  
4. 1.  I n cl usi o n Criteria  ........................................................................................................ 3 6  
4. 2.  E x cl usi o n Criteria  ....................................................................................................... 3 7  
4. 3.  Scree n Fail ures  ............................................................................................................ 3 8  
4. 4.  Re m o val of S u bjects fr o m T hera p y  ............................................................................ 3 9  
5.  S T U D Y D R U G/ T R E A T M E N T  ................................................................................. [ADDRESS_788297] ora ge  ........................................................................................................................ 4 1  
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 8 of 87 5.4. Blinding ......................................................................................................................41  
5.5. Drug Accountability ...................................................................................................42  
5.6. Treatment Compliance  ................................................................................................42  
5.7. Concomitant Therapy and Restrictions ......................................................................43  
6. STUDY PROCEDURES  ............................................................................................45  
6.1. Screening and Enrollment  ...........................................................................................45  
6.2. Study Day 1  ................................................................................................................46  
6.3. Study Week 2 (Day 15) ..............................................................................................47  
6.4. Study Week 4 (Day 29) ..............................................................................................48  
6.5. Study Week 8 (Day 57) ..............................................................................................49  
6.6. Study Week 12 (Day 85) ............................................................................................50  
6.7. Study Week 16 (Day 113) ..........................................................................................51  
6.8. Study Week 20 (Day 141) ..........................................................................................52  
6.9. Study Week 24 (Day 169) ..........................................................................................54  
6.10.  Study Week 28 (Day 197) ..........................................................................................55  
6.11.  Study Week 32 (Day 225) ..........................................................................................56  
6.12.  Study Week 36 (Day 253) ..........................................................................................57  
6.13.  Study Week 44 (Day 309) ..........................................................................................58  
6.14.  Early Termination Visit ..............................................................................................58  
7. STUDY ASSESSMENTS  ..........................................................................................59  
7.1. Efficacy Assessments  .................................................................................................59  
7.1.1.  Location and Extent of Hidradenitis Suppurativa Assessment ...................................59  
7.1.2.  Sartorius and Modified Sartorius Scores ....................................................................59  
7.1.3.  International Hidradenitis Suppurativa Severity Score System ..................................60  
7.1.4.  Hidradenitis Suppurativa- Physician Global Assessment (HS -PGA)  .........................60  
7.1.5.  Global Assessment of Skin Pain .................................................................................61  
7.1.6.  Health -Related Quality of Life Assessments  ..............................................................61  
7.1.7.  Health -Economic Information ....................................................................................61  
7.2. Safety Assessments  .....................................................................................................61  
7.2.1.  Physical Examinations and Vital Signs  ......................................................................61  
7.2.2.  Clinical Safety Laboratory Assessments  ....................................................................62  
7.2.3.  Adverse Events  ...........................................................................................................62  
[IP_ADDRESS].  Adverse Event Severity Assessment  ..........................................................................63  
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 9 of 87 [IP_ADDRESS].  Causality Assessment  .................................................................................................63  
[IP_ADDRESS].  Adverse Events of S pecial Interest (AESI)  ................................................................63  
[IP_ADDRESS].  Serious Adverse Events ..............................................................................................64  
[IP_ADDRESS].  SARs and S[LOCATION_003]Rs  .....................................................................................................64  
[IP_ADDRESS].  Laboratory Abnormalities  ...........................................................................................65  
[IP_ADDRESS].  Pregnancies  .................................................................................................................[ADDRESS_788298] Disposition  .....................................................................................................74  
Avacopan (CCX168)   Protocol CL016_168 
[ADDRESS_788299] ug Exposure and Compliance .......................................................................74  
8.8.11.  Handling of Missing Data ...........................................................................................75  
8.8.12.  Covariates and Subgroups ..........................................................................................75  
8.9. Interim Analyses  .........................................................................................................75  
9. STUDY COMPLETION AND TERMINATION  ......................................................75  
9.1. Study Completion  .......................................................................................................76  
9.2. Study Termination  ......................................................................................................76  
10. SUPPORTING DOCUMENTATION AND OPERATIONAL  
CONSIDERATIONS  ..................................................................................................76  
10.1.  Regulatory, Ethical, and Study Oversight Considerations .........................................76  
10.1.1.  Informed Consent .......................................................................................................76  
10.1.2.  Study Discontinuation and Closure ............................................................................77  
10.1.3.  Confidentiality and Privacy ........................................................................................77  
10.1.4.  Future Use of Stored Specimens and Data .................................................................77  
10.1.5.  Key Roles and Study Governance ..............................................................................78  
[IP_ADDRESS].  Investigator Responsibilities  .......................................................................................78  
[IP_ADDRESS].  Sponsor and Its Designees  ..........................................................................................78  
[IP_ADDRESS].  Institutional Review Boards/Ethics Committees  ........................................................[ADDRESS_788300] Keepi[INVESTIGATOR_007]  ...........................................................................80  
[IP_ADDRESS].  Data C ollection and Management Responsibilities  ....................................................80  
[IP_ADDRESS].  Study Records Retention ............................................................................................81  
10.1.10.  Protocol Deviations ....................................................................................................81  
10.1.11.  Protocol Modifications ...............................................................................................81  
10.1.12.  Study Registratio n, Use of Information and Publication ............................................82  
11. BENEFIT/RISK ASSESSM ENT  ...............................................................................82  
11.1.  Non-Clinical Evaluation  .............................................................................................82  
11.2.  Clinical Evaluation  .....................................................................................................83  
11.3.  Summary Benefit- Risk State ment  ..............................................................................85  
Avacopan (CCX168)   Protocol CL016_168 
[ADDRESS_788301] OF TABLES  
Table 1:  Avacopan/Placebo Treatment for the Three Study Groups ........................................34  
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 12 of 87 STUDY SYNOPSIS  
Name [CONTACT_596847], Inc.  Name [CONTACT_596848] (formerly CCX168)  Study Number :  
CL016_168 
Title  
A Randomized, Double-Blind, Placebo-Controlled, P arallel Group, Phase [ADDRESS_788302] s with Moderate to Severe Hidradenitis 
Suppurativa 
Study centers  
Multi- center s 
Study period  
29 months Phase of development  
Phase 2 
Background 
Hidraden itis suppurativa ( HS), also called acne inversa, is a chronic inflammatory skin disease 
characterized by [CONTACT_596794], abscess, sinus and fistula formation, and scarring of the 
skin, most commonly in apocrine gland rich areas such as the axilla, inf ramammary area, 
inguinal area, perineum, and perianal area. T herapy for subject s with HS includes local and 
systemic antibiotics, pain medication, and anti- TNF -α agents such as adalimumab. Acitretin is 
used in early stage disease. Other drugs such as cyclo sporin A, dapsone, and isotretinoin have 
been used with limited success.  
Studies have shown that HS is a neutrophil-driven disease, and that complement activation with the production of terminal fragment C5a may be important in the pathogenesis of the dise ase. 
The C5a- C5aR signaling axis is essential in mediating neutrophil activation and migration. 
Avacopan, an orally administered selective C5a receptor (C5aR) inhibitor, was shown to be 
effective and safe in a Phase [ADDRESS_788303] s with anti-neutrophil cytoplasmic autoantibody 
(ANCA) -associated vasculitis (AAV) and is being tested in a Phase [ADDRESS_788304] s with moderate to severe HS . 
Study Description 
The study is a randomized, double-blind, placebo -controlled, three -group Phase 2 trial  in 
approximately 390 subje cts with moderate to severe hidradenitis suppurativa (Hurle y Stage II or 
III). Subjects will be randomized 1:1:1 to a treatment of 10 mg avacopan twice daily, 30 mg 
avacopan twice daily or placebo for 12 weeks.  Other systemic treatments for HS including anti-
TNF -α treatments  are prohibited. Stable antibiotic therapy with doxycycline or minocycline is  
allowed as specified in the protocol. Subjects  treated  with 10 mg or 30 mg avacopan twice daily 
during the blinded , placebo -controlled 12-week treatment period  (Period 1) will be followed by 
[CONTACT_596795] (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 13 of 87 an additional  24-week , active  treatment period  (Period 2)  during which they will continue to 
receive the same dose regimen, either 10 mg or 30 mg avacopan twice daily . Subjects on 
placebo who complete Period 1 will be re-randomized 1:[ADDRESS_788305] s will be follo wed without study drug for 8 weeks before they exit the study . 
Objectives  
Primary Objectives:  
1. Evaluation of the efficacy o f avacopan compared to placebo in subject s with Hurley Stage II 
or III hidradenitis suppurativa (HS) based on subjects achieving a Hi dradenitis Suppurativa 
Clinical Response (HiSCR) after [ADDRESS_788306] a 50% 
reduction in abscess and inflammatory nodule count and no increase in abscess count and no 
increase in draining fistula count at Week 12 relative to baseline.  
2. Evaluation of the safety of avacopan compared to placebo in these subjects based on the adverse event incidence, changes from baseline in laboratory parameters, and vital signs.  
Secondary and Other O bjectives : 
1. Evaluation of the efficacy of avacopan compared to placebo in these subject s include: 
a. The subject’s global assessment of skin pain numeric rating scale (NRS),  
b. The modified Sartorius score, and  
c. Achieving an AN count of 0, 1, or 2. 
2.  Assessment of patient -reported outcomes including health- related quality -of-life changes 
based on the Short Form-36 version 2 (SF-36 v2), the EuroQOL- 5D-5L (EQ -5D- 5L), the 
Hidradenitis Suppurativa Quality of Life (HiSQOL) Index, the Dermatology Life Quality 
Index (DLQI), and the Work Productivity and Activity Impairment Questionnaire: Specific 
Health Problem (WPAI:SHP)  with avacopan compared to placebo. 
3. Evaluation of the pharmacokinetic profile of avacopan in subject s with HS.  
4. Evaluation of the safety and efficacy of avacopan treatment from Day [ADDRESS_788307] s with HS.  
5. Evaluation of the efficacy of avacopan compared to placebo in these subjects include: 
a. The Sartorius score, International HS Severity Scoring System ( IHS4 ) score, HS 
Physic ian Global Assessment ( HS-PGA), 
b. Proportion of subjects who experienced flare, who experienced loss of response during 
Period 2, who received oral antibiotic rescue therapy or lesion intervention , and  who 
received  disallowed opi[INVESTIGATOR_416266], and 
c. The duration of flare in days.  
6. Evaluation of health -economic information. 
Endpoints  
Endpoints will be evaluated by [CONTACT_1570]. 
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 14 of 87 Primary Efficacy Endpoint  
The proportion of subjects achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at 
Week 12. A response is defined as a reduction of at least  50% in abscess and inflammatory 
nodule count with no increase in abscess count and no increase in draining fistula count 
compared to baseline. 
Secondary E fficacy Endpoints : 
1. Reduction of IHS4 score relative to baseline at Week 12; 
2. Proportion of subjects achieving at least 30% reduction and at least [ADDRESS_788308]’s global assessment of skin pain (NRS30) in subjects with a Day [ADDRESS_788309] 3, evaluated at Week 12; weekly averages of daily pain will be calculated 
based on subjects’ daily diary recording of the worst pain experienced in the previous 24 hours; 
3. Change from D ay 1 to Week 12 in the modified Sartorius score to quantify the severity 
change of HS ; 
4. Proportion of subjects with baseline Hurley Stage II who achieved an abscess and inflammatory nodule count of 0, 1, or 2 at Week 12. 
Other  Efficacy E ndpoints : 
The following efficacy endpoints will be analyzed from Day 1 to each timepoint up to Week 44, where applicable: 
1. Proportion of subjects achieving HiSCR ; 
2. Proportion of subjects achieving at least 30% reduction and at least [ADDRESS_788310]’s global assessment of skin pain (NRS30), in subjects with a Day [ADDRESS_788311] 3;  
3. Proportion of subject s with baseline Hurley Stage II who achieved an abscess and 
inflammatory nodule count of 0, 1, or 2; 
4. Change from Day 1  in inflammator y nodule count, abscess count, draining fistula count, and 
total AN count; 
5. Change from Day 1 in the Sartorius score, modified Sartorius score, IHS4 score, and HS -
PGA to quantif y the severity change of HS;  
6. Change from Day 1  in patient-reported outcom es: SF -36 v2, EQ-5D- 5L, HiSQOL  and 
DLQI ; 
7. Proportion of subjects who experienced flare, defined by [CONTACT_2669] a 25% increase in AN counts with a minimum increase of 2 AN lesions relativ e to Day 1;  
8. Duration of flare in days (calculated from the day when flare is observed to the day prior to the observation that flare is no long er present; of note, there could be multiple periods that 
flares are observed, in which case, the total days from the multiple periods will be used); 
9. Proportion of subjects who experience at least 25% increase in draining fistula counts with a minimum increase of 2 draining fistula counts relative to Day 1;  
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 15 of 87 10. During Period 2 , Proportion of subjects with a loss of respo nse, (LOR) defined as loss of at 
least 50% of AN count improvement achieved from Period 1; 
11. Time to LOR during Period 2; 
12. Proportion of subjects who received  oral antibiotic rescue therapy ; 
13. Proportion of subjects who start disallowed opi[INVESTIGATOR_416266] ; 
14. Proportion of subjects who undergo lesion  intervention due to HS; 
15. Number of lesion interventions due to HS; 
16. Health -economic information: 
a. WPAI:SHP: Change from Day 1  to each timepoint during Period 1and Chan ge from 
Week 12  to each timepoint during Period 2 and  including the follow-up period; 
b. Hospi[INVESTIGATOR_602] (cumulative): Number of Hospi[INVESTIGATOR_596766], 
Number of days hospi[INVESTIGATOR_057], Number of days missed from work;  
c. Emergency or Urgent Care visit s (cumulative): Number of visits total and due to HS, 
Number of days (or hours where applicable) missed from work; 
d. Lesion interventions for HS : Number of days (or hours where applicable) missed from 
work due to HS lesion interventions. 
Safety endpoints: 
1. Subject  incidence of treatment -emergent serious adver se events, adverse events, and 
withdrawals due to adverse events;  
2. Change from D ay 1 and shifts from D ay 1 in all safety laboratory parameters;  
3. Change from D ay 1 in vital signs  and significant changes in physical examination 
abnormalities . 
Number of Subjec ts/Sample Size Assumptions : 
The study will enroll approximately [ADDRESS_788312] s in the placebo 
control group achieving a HiSCR at Week 12 is estimated to be approximately 30%. The 
attrition rate throughout the trial is estimated to  be approximately 7%. A sample size of 
approximately 130 subjects per treatment group (390 in total) at a Type I error rate of two -sided 
α = 0.05 provides approximately 90% power to detect a 20% superiority of avacopan compared to the placebo control group in HiSCR at Week 12, assuming an HiSCR at Week 12 of 50% in the avacopan group. 
Study Interventions/Methodology  
Eligible adult subjects (at least 18 years of age) with moderate to severe hidradenitis 
suppurativa (Hurl ey Stage II or III) as specified by t he eligibility criteria are allowed to enter 
the study. 
In Period 1, s ubject s will be randomized 1:1:1  to receive 10 mg avacopan twice daily, 30 mg 
avacopan twice daily or matching placebo for 12 weeks in a double-blind, placebo-controlled 
manner.  
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 16 of 87 To obtai n balance across treatment groups, a stratified randomization scheme will be 
implemented. The stratification factors and strata within each factor are listed below. Eligible 
subjects will be randomized with equal chance (i.e., 1:1:1) to one of the three treatment groups within each stratum based on a non- dynamic, list-based blocked randomization scheme. 
1. Hurley Stage (Stage II vs . III): 
a. Stage II disease: one or more widely separated recurrent abscesses with tract 
formation and scars, or 
b. Stage III disease: mu ltiple interconnected tracts and abscesses across an entire area, 
with diffuse or near diffuse involvement. 
2. Concomitant antibiotic therapy  (Yes vs . No)  
a. Concomitantly treated with doxycycline or minocycline  as the only allowed antibiotic 
treatment for HS , or 
b. No concomitant antibiotic therapy . 
3. Anti-TNF -α treatment  (Treatment naïve vs. P revious treatment ): 
a. Did not previously receive anti -TNF -α drug such as adalimumab or infliximab  (anti-
TNF -α drug naïve) , or 
b. Previously (but no longer) received an anti -TNF -α drug and 
• completed anti -TNF -α treatment  but may have relapsed , or 
• was i ntolerant to anti -TNF -α treatment , or 
• previously failed to respond or inadequately responded to anti -TNF -α treatment . 
Not more than 20% of subjects will be in stratum 2a.  
Subjects will be screened for eligibility based on the stage of the disease and their health status. 
The Screening period will be up to [ADDRESS_788313] s will take study 
drug t wice daily which  will continue for 12 weeks (84 days). Thereafter, all subject s will take 
avacopan study drug  for 24 weeks (168 days), after which all subjects will be followed for 
8 weeks (56 days) without taking study medication . Study procedures at each visit day are 
detailed in the Time and Events Table.  
Subjects  will be discontinued from the study when all the Study Week [ADDRESS_788314] s who  experience a flare of HS or need HS lesion intervention during the study will be 
treated by [CONTACT_596796]  5.7 Concomitant Therapy and Restrictions. 
These s ubjects will be requested to remain in the study and to complete all study procedures if 
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 17 of 87 possible. During this time, subjects may continue to receive the study drug if deemed  clinically 
feasible by [CONTACT_596797]  5.7. 
Discontinuation of study medication due to inadequate or worsening response in  Period 2:  
Unless prohibited for safety reasons, deemed inappropriate by [CONTACT_737], or subject 
withdraws consent, all subjects are allowed to enter Period 2. Subjects in Period 2 will 
discontinue taking study medication if at two consecutive protocol- specified visits  ≥14 days 
apart,  the AN count increases by [CONTACT_726] 50% compared to the AN count at Week 12. 
However, these subjects will be requested to remain in the study and to complete all study procedures if possible. 
Criteria for Inclusion  
1. Aged at least 1 8 years of age; 
2. Clinical diagnosis of HS (Hurley Stage II or III), confirmed by a dermatologist,  for a t least 
[ADDRESS_788315] formation and scars ; Stage III disease is 
defined as having multiple interconnected tracts and abscesses across an  entire anatomical 
area, with diffuse or near diffuse involvement. 
3. HS lesions a re present in at least [ADDRESS_788316] anatomic areas (e.g., left and right axilla; or left 
axilla and left inguino-crural fold), one of which i s Hurley Stage II or Hurley Stage III ; 
4. Inadequate or loss of response to a systemic course of antibiotics of [ADDRESS_788317] who has completed less than 90 days of antibiotic treatment may be allowed into the study upon discussion with the Medical Moni tor if: 1) the subject has demonstrated 
intolerance to or contraindication for antibiotics to treat HS , or 2) it was determined by [CONTACT_596798] [ADDRESS_788318] and a continued antibiotic therapy would therefore not be indicated.  
Inadequate or loss of response is defined if the following was observed despi[INVESTIGATOR_596767] : 
a. Progression of Hurley Stage (i.e., the Hurley Stage of at least one affected anatomic 
region progressed from I→II, II→III, or I→III);  
b. Subject required at least one intervention (e.g., incision and drainage or intralesional injection of corticosteroid); 
c. Subject experienced pain interfering with activities of daily living, with unsatisfactory relief from over -the-counter analgesics (e.g., ibuprofen or acetaminophen); 
d. Subject experienced pain requiring opi[INVESTIGATOR_2438], including tramadol; 
e. Subject experienced drainage interfering with activities of daily living (e.g., requires 
multiple dressing changes and/or changes of clothes daily); 
f. Subject experienced an increase in the number of anatomic regions affected by [CONTACT_156889];  
g. Subject experienced at least one new abscess or one new draining fistula.  
5. Must have at least 5 inflammatory nodules or abscesses at S creening;  
6. Must agree to use a topi[INVESTIGATOR_596768]; topi[INVESTIGATOR_596769], triclosan, benzoyl peroxide, or diluted 
bleach in bath water;  
Avacopan (CCX168)   Protocol CL016_168 
[ADDRESS_788319] three months after study completion . Adequate 
contraception is defined as resulting in a failure rate of less than 1% per year (combined 
estrogen and progestogen [oral, intravaginal, or transdermal], or progestogen-only hormonal 
contraception where inhibition of ovulation is the primary mode of action [ oral, injectable, 
or implantable ], intra-uterine device, intra- uterine hormone releasing system, bilateral tubal 
occlusion, vasectomized partner, or true [absolute] sexual abstinence, i.e., in line with the preferred and usual lifestyle of the subject ). Male subject s with partners of childbearing 
potential may participate in the study if they had a vasectomy at least [ADDRESS_788320] three months after study completion. In addition,  a barrier meth od (i.e., condom, 
cervical cap, or diaphragm ) must  be used during intercourse between a male study subject 
and a female partner of childbearing potential; 
8. Willing and able to give written Informed Consent and to comply with the requirements of 
the study protocol; 
9. Judged by [CONTACT_596799] , based on medical history, 
physical examination (including electrocardiogram [ECG]), and clinical laboratory assessments. Subject s with clinical laboratory values that are outside of norm al limits (other 
than those specified in the Exclusion Criteria) and/or with other abnormal clinical findings that are judged by [CONTACT_596800] , may 
be entered into the study. 
Criteria for Exclusion  
1. Pregnant or breast -feeding;  
2. Any other skin disease that may interfere with the assessment of HS, such as a viral or fungal skin infection; 
3. Rapi[INVESTIGATOR_10480], expanding HS within 30 days prior to S creening;  
4. More than 20 draining fistulae at S creening;  
5. Any anti-TNF -α treatment for HS or for other conditions prior to Day 1 visit will be 
prohibited. Exception: Subjects who were previously treated with an anti -TNF -α drug and 
discontinued treatment >12 weeks prior to Day 1 visit are allowed for enrollment ; 
6. Syste mic antibiotics are generally excluded. Exception: subjects on systemic antibiotic 
treatment with doxycycline or minocycline who have been on a stable dose for at least [ADDRESS_788321] s will be 
allowed ; 
7. Topi[INVESTIGATOR_596770] 14 days prior to D ay 1; 
8. Have started a topi[INVESTIGATOR_596771] 14 days prior to S creening or is 
anticipated to start during the screening period. Topi[INVESTIGATOR_596772] >14 days prior to Screening is allowed ; 
Avacopan (CCX168)   Protocol CL016_168 
[ADDRESS_788322] on HS , including systemic antibiotic 
therapy, biologics and other systemic therapi[INVESTIGATOR_596773] , cyclosporine, 
retinoids, and fumaric acid esters, etc. , within a minimum of  30 days or 5 half- lives 
(whichever is longer) after taking the last dose; 
10.  Have received within 14 days prior to Day 1  visit or is expected to require during the study 
oral or transdermal opi[INVESTIGATOR_2467] (except for tramadol) for any reason ; non-opi[INVESTIGATOR_596774] a stable dose for at least 14 days prior to the Day 
1 visit (“ as needed ” dosing is not considered to be a stable dose); 
11. Currently taking a strong inducer of the cytochrome P450 3A4 (CYP3A4) enzyme, such as 
carbamazepi[INVESTIGATOR_050], phenobarbital, phenytoin, rifampin, or St. John’s wort; 
12. Any of the following within 12 weeks prior to S creening: s ymptomatic congestive heart 
failure requiring prescription medication, unstable angina (unless successfully treated with stent or by[CONTACT_4897]) , clinically significant cardiac arrhythmia, myocardial infarction or 
stroke; 
13. History or presence of any form of cancer within the [ADDRESS_788323] carcinoma in situ that has been excised or resected completely and 
is without evidence of local recurrence or metastasis;  
14. Evidence of tuberculosis based on interferon γ release assay (IGRA); 
15. HBV, HCV, or HIV viral screening test d one at Screening or within 6 weeks prior to 
screening showing evidence of active or chronic viral infection ; 
16. Received a live vaccine within 4 weeks prior to Screening;  
17. WBC count less than 3500/μL, or neutrophil count less than 1500/μL, or lymphocyte count less than 500/µL before start of dosing; 
18. Evidence of hepatic disease: AST, ALT, alkaline phosphatase, or bilirubin >3 times  the 
upper limit of normal before the start of dosing; 
19. Clinically significant abnormal electrocardiogram (ECG ) during S creening  which , in the 
opi[INVESTIGATOR_689], may place the subject at unacceptable risk for study participation ; 
20. Known hypersensitivity to avacopan  or inactive ingredients of the avacopan  capsules 
(including gelatin, poly ethylene glycol, or macrogolglycerol hydro xystearate [EP, European 
Pharmacopoeia (EP) ] known also as polyoxyl 40 hydrogenated castor oil [ NF, National 
Formulary]) or Crem ophor
® RH 40; 
21. Participated in any clinical study of an investigational product within [ADDRESS_788324] dose; 
22. History or presence of any medical condition or disease which, in the opi[INVESTIGATOR_689], may place the subject  at unacceptable risk for study participation . 
Avacopan (CCX168)   Protocol CL016_168 
[ADDRESS_788325] gelatin capsules containing 10 mg avacopan or placebo administered orally . 
Avacopan  and placebo bottles and capsules will be identical in appearance.  
Subjects  will be asked to take 3 capsules of study drug orally with water and preferably with 
food every morning, and 3 capsules with water and  preferably with food in the evening 
approximately 12 hours after the morning dose, as instructed. Study drug will be taken for 36 
weeks (252 days ) continuously.  
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 21 of 87 STUDY SCHEMA  
 
   Period 1   Period 2    
 Screening  
  Double -Blind Treatment  
  Active  Treatment     Follow -up  
 
Eligibility 
Assessments   
 Group A: Placebo b.i.d.  
Group B: Avacopan 10 mg b.i.d . 
Group C: Avaco pan 30 mg b.i.d.  
  
Avacopan 10 mg b.i.d. 
Avacopan 30 mg b.i.d . 
Avacopan 10 mg b.i.d. 
Avacopan 30 mg b.i.d .  
No study  
treatment      
    
        
        
Duration  ≤ 28 days   84 days  
(12 weeks)    168 days  (24 weeks)   56 days  
(8 weeks)  
Study 
Visits  One or more 
visits to 
complete 
screening 
procedures   Day 1 and, Weeks 2, 4, 8 and  12  Weeks 16, 20, 24, 28, 
32, 36   Week 44  
 / -----
--
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 22 of 87 TIME AND EVENTS TABLE  
 Screening Period 1  
Double-Blind Treatment  Period 2  
Active Treatment  Follow -
up 
Study Week1 ≤4 weeks1  2 4 8 12 16 20 24 28 32 36 44 
Study Day1 ≤28 days1 1 15 29 57 85 113 141 169 197 225 253 309 
 -7 
days              
Informed consent  X              
Review 
inclusion/exclusion 
criteria  X              
Demographics, 
medical history, 
prior treatments  X              
Physical 
examination2 X  X3 X X X X X X X X X X X 
Vital signs X  X3 X X X X X X X X X X X 
Serum pregnancy 
test for women of 
childbearing 
potential  X  X  X X X X X X X X X   
Urine pregnancy 
test for women of 
childbearing 
potential    X3            
HIV, HBV, HCV 
testing  X              
Screening for 
tuberculosis4 X              
12-Lead ECG  X      X       X 
Serum chemistry 
incl. Liver Function Tests, Hematology
 X  X3 X X X X X X X X X X X 
Urinalysis  X  X3  X X X X X X X X X X 
Biomarker plasma 
sample collection15   X15    X      X  
Stratification and 
randomization    X    X10        
Record location 
and number of HS inflammatory nodules, abscesses, 
fistulae, and scars  X  X3 X X X X X X X X X X X 
Record Hurley 
Stage  X              
Subject global 
assessment of skin pain daily diary 
recording5   X3→ → → → → → → → → → → → →X 
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 23 of 87  Screening Period 1  
Double-Blind Treatment  Period 2  
Active Treatment  Follow -
up 
Study Week1 ≤4 weeks1  2 4 8 12 16 20 24 28 32 36 44 
Study Day1 ≤[ADDRESS_788326] IHS4 
score7    X3 X X X X X X X X X X X 
HS-PGA14   X3 X X X X X X X X X X X 
SF-36 v2 and EQ -
5D-5L Patient -
Reported 
Outcomes8    X3  X  X X   X  X X 
HiSQOL Index8 
Health -Economic 
Information13    X3
X X X X X X X X X X X X 
Study drug 
dispensing    X3      X     X       
Study drug 
compliance    X X X X X X X X X X X  
Study drug 
accountability11       X11   X11   X11  
PK plasma sample 
collection9   X X X X X X X  X  X X 
Concomitant 
medications  X  X X  X X X X X X X X X X 
Adverse event 
assessment  X  X X X X X X X X X X X X 
1Screening period m ay be exceeded by [CONTACT_8622] 3 days. W eek 1 through 36 visits may occur within a ± 2-day window. 
The Week 44 visit may occur within a ± 4-day window.  
2Physical examination will include body weight measurements. Height will be measured only at Screening.  
3These  procedures must be performed before taking the first dose of blinded study drug ( avacopan  or placebo ). 
4Screening for tuberculosis : see exclusion criteria for specifics . 
5Subject s will record the maximum severity pain on a numeric rating scale from 0 (no  skin pain) to 10 (skin pain as 
bad as can be imagined) in a daily diary from one week prior to Day 1 through the Week 44 visit.  
6Twelve body areas will be evaluated to calculate the Sartorius and  modified Sartorius score s: left and right axillae, 
left and  right inframammary areas, intermammary area, left and right buttocks, left and right inguino -crural folds, 
perianal area, perineal area, and other. The presence of nodules, abscesses, fistulae, scars, and other findings will be recorded. The longest distance between two lesions and whether lesions are separated by [CONTACT_596801].
 
7IHS4 score (points) = (number of nodules multiplied by 1) + (number of abscesses multiplied by 2) + [number of 
draining tunnels (fistulae/sinuses) multiplied by 4].  A score of 3 or less signifies mild HS, a score of 4– 10 signifies 
moderate HS and a score of 11 or higher signifies severe HS. 
8“Patient- reported outcomes ” (PRO s) include the  SF-36 v2, EQ -5D-5L, HiSQOL , DLQI , and WPAI -SHP 
questionnaires . The SF -36 v2 and EQ-5D-5L instruments are widely accepted global non -disease -specific tools to 
measure changes in subjects’ health -related quality of life. The HiSQOL index (an HS -specific instrument) and 
DLQI instruments are designed to measure the impact of HS or skin disease on subjects’ quality of life. The 
WPAI:SHP assesses the effect of general and specific health conditions on productivity losses.  
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 24 of 87 9 PK blood sample will be collected prior to the morning dose on Day 1 and at 0.5, 1, 2, and 3 (+/- 5 minutes) hours 
following dosing. Single PK samples will be  collected pre- dosing at the  subsequent visits as indicated. The date 
and time of the PK sample collection will be recorded. The date and time of the last dose of study drug  prior to the 
PK sample collection will also  be recorded.  On study visit days when PK samples are collected, it is preferable 
that the subjects take the morning dose of study drug at the site following the collection of PK samples. PK will be 
performed in up to [ADDRESS_788327] for collection of PK samples . 
10 Subjects on placebo who complete the blinded, placebo -controlled 12- week period (Period 1)  will be re -
randomized 1:1 to receive 10 mg or 30 mg avacopan twice daily during the 24- week active treatment period  
(Period 2) . 
11At Week 12, 24, and 36 visits, full drug accountabilit y will be conducted  on returned study drug . 
12If consented, photography  will be used for  the purpose of publications and lesio n assessment comparison.  If 
feasible, i t is recommended that photographs be taken at every visit.  
13Health -economic information  include hospi[INVESTIGATOR_602], emergency or urgent care visits, and lesion interventions 
due to HS. The WPAI:SHP questionnaire admi nistration will follow the Patient -Reported Outcomes schedule.  
14HS-PGA is an ordinal scale specific to HS that categorizes subjects into clear, minimal, mild, moderate, severe, or 
very severe disease. 
15Biomarker plasma sample will be collected at Day 1, Week 12, and  Week [ADDRESS_788328] dose of study drug.  
 
Avacopan (CCX168)   Protocol CL016_168 
[ADDRESS_788329]  
aHUS  atypi[INVESTIGATOR_596775] (count)  
ANA  antinuclear an tibodies  
ANC  absolute neutrophil count  
ANCA  anti-neutrophil cytoplasmic autoantibody  
ANCOVA  analysis of covariance  
AST  aspartate aminotransferase  
AT Aminotransferase  
ATC Anatomic Therapeutic Chemistry  
AUC  area under the plasma concentration -time cur ve 
b.i.d.  twice daily  
BVAS  Birmingham Vasculitis Activity Score  
C3 complement component 3  
C3a complement component 3a fragment  
C4a complement component 4 a fragment  
C5a complement component 5a fragment  
C5aR  receptor for C5a  
C5b-9 membrane attack com plex or terminal complement complex  
CA competent authority  
Cmax maximum (maximal) plasma concentration  
Cmin minimum plasma concentration  
CMH  Cochran -Mantel -Haenszel  
CPK  creatine phosphokinase  
CRA  Clinical Research Associate  
CRF  Case Report F orm 
CRO  clinical research organization  
CSR  clinical study report  
CYP3A4  cytochrome P450 3A4  
DLQI   Dermatology Life Quality Index  
DMC  data monitoring committee  
EC Ethics Committee  
ECG  Electrocardiogram  
eCRF  electronic case report form  
EDC  electronic data c apture  
EIA  enzyme immunoassay  
EP European Pharmacopoeia  
EQ-5D-5L EuroQuality of Life -5 Domains -5 Levels  
FDA  Food and Drug Administration  
g Gram 
GCP  Good Clinical Practice  
HBV  hepatitis B virus  
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 26 of 87 HCV  hepatitis C virus  
hERG  potassium channel encoded by [CONTACT_596802] -à-gogo related gene  
HiSCR  hidradenitis suppurativa clinical response  
HiSQOL  Hidradenitis Suppurativa Quality of Life 
HIV human immunodeficiency virus  
HS hidradenitis suppurativa  
HS-PGA   Hidradenitis Suppurativa -Physician Global Asse ssment  
ICH International Conference on Harmonisation  
IC50 concentration associated with 50% inhibition  
Ig Immunoglobulin  
IgAN  immunoglobulin A nephropathy  
IGRA  interferon γ release assay  
IHS4  International HS Severity Scoring System  
IND Investigational New Drug  
INR International normalized ratio  
IRB Institutional Review Board  
IRT interactive response technology  
ITT intent -to-treat 
IV intravenous(ly)  
kDa Kilodalton  
kg Kilogram  
LOCF  last observation carried forward  
LOR  loss of response  
MAC  membrane attack complex  
MCP -[ADDRESS_788330] 30% reduction and at least [ADDRESS_788331]’s global assessment of skin pain on a 
numeric rating scale  
PCR  polymerase chain reaction  
PK pharmacokinetic(s)  
PP Per-protocol  
PRO  patient -reported outcome  
PT prothrombin time  
QA quality assurance  
QC quality c ontrol  
QT/QTc  Q-T interval on ECG; corrected Q -T interval  
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 27 of 87 RBC  red blood cell(s)  
RNA  ribonucleic acid  
SAE  serious adverse event  
SAP statistical analysis plan  
SAR  serious adverse reaction  
SD standard deviation  
SEM  standard error of the mean  
SF-[ADDRESS_788332]  upper limit of normal  
WBC white blood cell  
WHODD  World Health Organization Drug Dictionary  
WPAI:SHP  Work Productivity and Activity Impairment Questionnaire: Specific Health 
Problem  
Avacopan (CCX168)   Protocol CL016_168 
[ADDRESS_788333] generates biologic ally active fragments of 
complement proteins, e.g., C3a, C4a and C5a anaphylatoxins, and the C5b- 9 membrane attack 
complex (MAC) or terminal complement complex (TCC), all of which mediate inflammatory 
responses by [CONTACT_596803], activating macrophages, neutrophils, platelets, mast cells and endothelial cells and by [CONTACT_596804], cytolysis , and tissue 
injury. 
C5a is one of the most potent pro- inflammatory mediators of the complement system, being at 
least [ADDRESS_788334] cell degranulation, and inducing release of lysosomal proteases an d oxidative 
free radicals. The anaphylactic and chemotactic effects of C5a are mediated through its 
interaction with the C5aR, a G protein-coupled receptor expressed on human neutrophils, 
monocytes, basophils, eosinophils, renal glomerular tissues, and lung smooth muscle and endothelial cells.  
Avacopan  (formerly CCX168) is an orally administered, small molecule, selective inhibitor of 
the complement 5a receptor (C5aR).  
As measured in vitro , avacopan  functionally inhibits C5a -mediated chemotaxis, displaces 
[
125I]-C5a from human C5aR, and inhibits C5a- mediated increase in cytoplasmic calcium levels 
with a potency (IC 50) of 0.2 to 0.9 nM in buffer (Bekker et al, 2016) . 
Avacopan  was also evaluated for its ability to inhibit the C5a -mediated chemotaxis of 
neutrophils in freshly isolated human whole blood. Avacopan  produced 50% inhibition (IC 50) of 
C5a-mediation neutrophil migration in this assay at a concentration of 1.7 nM; 90% inhibition (A
10 value) occurred  at an avacopan  concentration of 15.4 nM. Avacopan  also inhibits C5aR in 
cynomolgus monkeys and hamsters with potencies similar to that observed with human whole blood. However, avacopan possesses moderate potency for rabbit C5aR (IC
50 ~ 1.4 µM) and 
lacks affinity for mouse, rat, or dog C5aR (IC 50 >10 µM). 
The efficacy of avacopan  was assessed u sing genetically -modified mice where the mouse C5aR 
coding region was substituted for the human C5aR coding region. In these studies, intravenous injection of mouse anti-myeloperoxidase (anti-MPO) IgG into the human C5aR knock- in mice 
caused glomerulonephritis in a manner mimicking anti-neutrophil cytoplasmic autoantibody 
(ANCA) disease in humans. At daily oral doses of 30 mg/kg avacopan , a marked inhibition of 
anti-MPO induced glomerulonephritis was documented histolog ically, as assessed by [CONTACT_596805] -containing glomeruli. These results were consistent with reduced 
protein, leukocytes, and red blood cells in the urine, and reduced serum blood urea nitrogen and 
creatinine in mice receiving avacopan ( Xiao et al, 2014).  
Avacopan (CCX168)   Protocol CL016_168 
[ADDRESS_788335] previously been completed. 
Avacopan was generally well tolerated in these studies.  A Phase 3 study in subjects with AAV 
previously completed enrollment but follow up is ongoing and the study remain s blinded. 
Another Phase 2 study in subjects with C3 glomerulopathy is currently enrolling and is also 
blinded. 
Results from a mass balance study ( CL004_168) showed that avacopan was mostly metabolized 
in the liver ; in vitro metabolism studies showed that avacopan was primarily metabolized 
through cytochrome P450 3A4 ( CYP3A4 ). 
Avacopan did not show evidence of a detrimental effect on QT/QTc based on results from an 
intensive ECG study ( CL007_168).  
Co-administration of the strong CYP3A4 enzyme inducer rifampi[INVESTIGATOR_596776]008_168 
resulted in an approximately 93% reduction of systemic exposure of avacopan, which may result in a loss of efficacy of avacopan. Therefore, the use of strong CYP3A4 enzyme induc ers with 
avacopan is an exclusion criterion for this study. Co-administration of the strong CYP3A4 
enzyme inhibitor itraconazole resulted in a 119% increase of systemic exposure of avacopan. Concomitant use of avacopan with strong CYP3A4 enzyme inhibitors should be used with caution. 
Two Phase [ADDRESS_788336] s with ANCA- associated vasculitis ( AAV) were 
conducted. The first study in 67 subjects ( CL002_168) included three dose groups: 30 mg 
avacopan twice daily plus low dose prednisone (20 mg/day), 30 mg avacopan twice daily plus no 
prednisone, and placebo plus full dose prednisone (60 mg/day). All subjects received either IV cyclophosphamide or rituximab as standard of care treatment. Avacopan, alone or with low dose 
prednisone, was associated with a rapid onset of action based on improvements in a global 
disease activity index  (the Birmingham Vasculitis Activity Score , BVAS), and improvements in 
renal parameters such as albuminuria, and health- related quality of life measurements over a 12 -
week treatment period  (Jayne et al, 2017) . The steady state mean avacopan plasma concentration 
was approximately 204 ng/mL in these subjects, corresponding to >95% projected inhibition of 
the C5aR in the circulati on. Avacopan also showed a favorable safety p rofile  in this study . 
The second study in 42 subjects ( CL003_168 ) included three dose groups: 10 mg avacopan twice 
daily plus full dose prednisone (60 mg), [ADDRESS_788337] of care treatment. Avacopan appeared to be safe when added on top of full 
dose prednisone plus cyclophosphamide or rituximab, and the efficacy data support 30 mg avacopan twice daily as the therapeutic dose in AAV . Refer to the Investigator’s Brochure for 
more details.  
An open-label Phase 2 clinical trial in 7 subjects with IgA nephropathy (IgAN) has been conducted (CL005_168). Results showed that avacopan therapy was associated with  
improve ment in proteinuria over a 12-week treatment period; 3 of 7 subjects showed 
approximately 50% decrease in either urinary protein:creatinine ratio (UPCR) or albumin:creatinine ratio (UACR). An open- label Phase 2 clinical trial in 6 subjects with atypi[INVESTIGATOR_29601] (aHUS) was conducted (CL006_168). Results showed that serum 
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 30 of 87 collected from subjects dosed with avacopan caused a mean percent reduction of 82% in 
thrombus size compared to baseline in an ex vivo assay. 
A Phase [ADDRESS_788338] s with C3 
glomerulopathy is ongoing ( CL011_168) . The study remains blinded. 
A Phase 3 clinical trial with a target enrollment of approximately 300 subjects with AAV 
previously completed enrollment and follow up is ongoing (ADVOCATE, CL010_168). In this 
study in subjects  with AAV, avacopan (or placebo) is compared with standard of care 
glucocorticoids as added medications to background therapy of either rituximab or 
cyclophosphamide followed by [CONTACT_596806]. The  study remains blinded. 
The Reference Safety Information section of the Investigator ’s Brochure has been  updated to 
include the potential risk of urticaria, angioedema, and of hepatotoxicity, and to state that general gastrointestinal adverse events (e.g. , nausea, diarrhea) observed in Phase [ADDRESS_788339] been modified. 
A benefit and risk assessment of avacopan is presented in Section  11; detailed information about 
non-clinical and clinical trials with avacopan is presented in the Investigator’s Brochure. Results 
from nonclinical and clinical studies conducted to date showed a positive risk- benefit profile of 
avacopan in treatment of subject s with HS (Section  11). 
1.3. Rationale for the Study  
Hidradenitis suppurativa (HS), also called acne inversa, is a chronic inflammatory skin disease 
characterized by [CONTACT_596794], abscess, si nus and fistula formation, and scarring of the 
skin, most commonly in apocrine gland rich areas such as the axilla, inframammary area, 
inguinal area, perineum, and perianal area. In its moderate and severe forms, HS is debilitating 
and causes significant d iscomfort, pain, anxiety and depression, as well as impairment of quality 
of life. The exact cause of HS has not been identified, although genetic defects in the gene 
encoding for gamma- secretase have been described in subject s with HS. Potential target pr oteins 
include Notch, E-cadherin, and nicastrin. Notch plays an important role in hair follicle 
development, and a defect in Notch may lead to formation of epi[INVESTIGATOR_596777], dysregulation of 
normal T-cell mediated immune responses, and suppression of Toll-like receptor-4-induced pro-inflammatory macrophage mediated cytokine responses ( Radtke et al, 2010 ; Wang et al, 2010). 
Smoking and obesity have been associated with HS ( Prens and Deckers, 2015).  
Therapy for subjects with HS includes local and systemic antibiotics, pain medication, and anti-
TNF -α agents such as adalimumab. Acitretin is used in early stage disease. Other drugs such as 
cyclosporin A, dapsone, and isotretinoin have been used with limited success ( Napolitano et al , 
2017). In more advanced cases,  a multifaceted approach may be adopted, where surgical therapy 
is used to remove the chronic components of HS which are not expected to respond to medical 
therapy (e.g., scarring, fistulas, and sinus tracts), and long- term systemic medical therapy is used  
to treat the acute or sub -chronic manifestations of HS (e.g., abscesses and inflammatory 
nodules). 
Avacopan (CCX168)   Protocol CL016_168 
[ADDRESS_788340] shown that HS is a neutrophil-driven disease, and that complement activation with 
the production of terminal fragment C5a may be important in the pathogenesis of the disease 
(Kanni et al, 2018) . The C5a- C5aR signaling axis is essential in mediating neutrophil activation 
and migration. Recently it is has been reported that circulating C5a and C5b- 9 levels were 
significantly greater in HS patients , further adding to the relevance of C5a-C5aR an important 
mechanistic contributor to the disease process. More importantly, plasma from HS patients activates neutrophils (CD11b upregulation) ex vivo, and this activation can be blocked by a 
neutralizing an tibody against C5a (IFX-1; Kanni T, et al. 2018) , suggesting that C5a may be a 
critical factor in driving neutrophil activation and infiltration in the diseased tissue in HS 
patients.  An anti-C5a agent, IFX-1, has shown efficacy in a Phase [ADDRESS_788341] ing a role for 
C5a blocking agents in the treatment of HS ( Guo et al, 2017) . 
Avacopan, an orally administered, C5a receptor (C5aR) selective agent, was shown to be effective and safe in a Phase [ADDRESS_788342] s with AAV ( Jayne et al, 2017)  and is being tested 
in a Phase [ADDRESS_788343] whether avacopan is effective in treating patients  with moderate 
to severe HS.  
This clinical trial will be conducted in compliance with the protocol, good clinical practice (GCP), and appl icable regulatory requirements.  
2. OBJECTIVES 
2.1. Primary Objective s 
The primary objectives of this study include: 
1. Evaluation of the efficacy o f avacopan compared to placebo in subject s with Hurley Stage II 
or III hidradenitis suppurativa (HS) based on subjects achieving a Hidradenitis Suppurativa 
Clinical Response (HiSCR) after [ADDRESS_788344] a 50% 
reduction in abscess and inflammatory nodule count with no increase in abscess count and no 
increase in draining fistula count at Week 12 relative to baseline.  
2. Evaluation of the safety of avacopan compared to placebo in these subjects based on the 
adverse event incidence, changes from baseline in laboratory parameters, and vital signs.  
2.2. Secondary and Other Objectives  
The secondary and other objectives of this study include: 
1. Evaluation of the efficacy of avacopan compared to placebo in these subject s include: 
a. The subject’s global assessment of skin pain numeric rating scale (NRS),  
b. The modified Sartorius score, and  
c. Achieving an AN cou nt of 0, 1, or 2. 
2. Assessment of patient -reported outcomes including health- related quality -of-life changes 
based on the Short Form-36 version 2 (SF-36 v2), the EuroQOL- 5D-5L (EQ -5D- 5L), the 
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 32 of 87 Hidradenitis Suppurativa Quality of Life (HiSQOL) Index, the Dermatology Life Quality 
Index (DLQI) , and the Work Productivity and Activity Impairment Questionnaire: Specific 
Health Problem (WPAI:SHP)  with avacopan compared to placebo. 
3. Evaluation of the pharmacokinetic profile of avacopan in subject s with HS.  
4. Evaluation of the safety and efficacy of avacopan treatment from Day [ADDRESS_788345] s with HS.  
5. Evaluation of the efficacy of avacopan compared to placebo in these subjects include: 
a. The Sartorius score, International HS Severity Scoring Sys tem (IHS4) score, HS 
Physic ian Global Assessment (HS -PGA),  
b. Proportion of subjects who experienced flare, who experienced loss of response during 
Period 2, who received oral antibiotic rescue therapy  or lesion intervention, and  who 
received  disallowed opi[INVESTIGATOR_416266], and  
c. The duration of flare in days. 
6. Evaluation of health -economic information . 
3. STUDY DESIGN 
The study is a randomized, double-blind, placebo-controlled, three-group Phase 2 trial in 
approximately 390 subjects with moderate to severe hidradenitis suppurativa (Hurley S tage II or 
III). Subjects will be randomized 1:1:1 to a treatment of 10 mg avacopan twice daily, 30 mg avacopan twice daily or placebo for 12 weeks. Other systemic treatments for HS including anti-
TNF -α treatments are prohibited. Stable antibiotic therapy with doxycycline or minocycline is 
allowed as specified in the protocol. Subjects treated with 10 mg or 30 mg twice daily during the 
blinded, placebo-controlled 12-week treatment period (Period 1) will be followed by [CONTACT_102160] 24- week,  active treatment period (Period 2) during which they will continue to 
receive the same dose regimen, either 10 mg or 30 mg avacopan twice daily. Subjects on placebo who complete Period 1 will be re -randomized 1:[ADDRESS_788346] , study site  personnel or the Sponsor. Thereafter, all subjects will 
be followed for 8 weeks without study drug before th ey exit the study.  
To obtain balance across treatment groups, a stratified randomization scheme will be implemented. The stratification factors and strata within each factor are listed below.  
3.1. Stratification and Randomization  
1. Hurley Stage (Stage II vs . III) 
a. Stage II disease: one or more widely separated recurrent abscesses with tract formation 
and scars, or  
b. Stage III disease: multiple interconnected tracts and abscesses across an entire area, with diffuse or near diffuse involvement. 
2.  Concomitant  antibiotic  therapy (Yes vs . No)  
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 33 of 87 a. Concomitantly treated with doxycycline or minocycline as the only allowed antibiotic 
treatment for HS , or 
b. No concomitant antibiotic therapy . 
3. Anti-TNF -α treatment (Treatment naïve vs. Previous treatment):  
a. Did not previously receive anti- TNF -α drug such as adalimumab or infliximab ( anti-
TNF -α drug naïve), or 
b. Previously (but no longer) received an anti- TNF -α drug and 
• completed anti -TNF -α treatment  but may have relapsed , or 
• was i ntolerant to anti -TNF -α treatment , or 
• previously failed to respond or inadequately responded to anti -TNF -α treatment . 
Not more than 20% of subjects will be in stratum 2a  as described above. 
Eligible subjects will be randomized with equal chance (i.e. , 1:1:1) to one of the three treatment 
groups within each stratum based on a non- dynamic, list-based blocked randomization scheme. 
1) Placebo twice daily  
2) Avacopan 10 mg twice daily 
3) Avacopan 30 mg twice daily 
3.2. Study Treatments  
Treatments for each group are shown in  Table 1.  
The treatment period  is 36 weeks ( 252 days), followed by [CONTACT_1629] 8- week (56 days) follow-up period 
without taking study medication . Subjects will be randomized 1:1:[ADDRESS_788347] 
12 weeks  (Period 1). Subjects randomized to 10 mg and 30 mg a vacopan in Period 1 will 
continue with the same drug regimen during the next 24- week active drug treatment period  
(Period 2). Subjects randomized to placebo in Period 1 will be re -randomized to receive either 10 
mg or 30 mg a vacopan b.i.d. in Period 2. Study treatment-group specific drug kits will be 
dispensed at relevant study visits. Detailed information about the study drug kits, dispensation 
and accountability is available in the Study Pharmacy Manual . 
Study drug will be taken as described in Section  5.2. 
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 34 of 87 Table 1: Avacopan/Placebo Treatment for the Three Study Groups  
 Period 1  
(12-Week Placebo -
Controlled Treatment )  Period 2  
(24-Week Active Drug 
Treatment )  
Group A 
Placebo  Kit # 1  Re-randomized  
50% to Kit # 2 
50% to Kit # 3 
Group B 
10 mg Avacopan  Kit #  2 Kit # 2  
Group C 
30 mg Avacopan Kit # 3  Kit # [ADDRESS_788348] s will take study drug twice daily, which will 
continue for 12 weeks (84 days). Thereafter, all subject s will take avacopan study drug for 24 
weeks (168 days), after which they will be followed for 8 weeks (56 days) without taking study 
drug. Study procedures at each visit day are detailed in the Time and Events Table.  
Subjects will exit the study when all the Study Week [ADDRESS_788349] been completed. 
Subjects who experience a flare of HS during the study will be treated by [CONTACT_737] , which 
may include a maximum 1 -week course of antibiotic rescue treatment with doxycycline or 
minocycline  or intralesional Kenalog
 rescue injections  (triamcinolone acetonide, [ADDRESS_788350] within a period no longer than 1 week). These s ubjects will be requested to 
remain in the study and to complete all study procedures if possible. During this time, subjects may continue to receive the study drug , if deemed clinically feasible  by [CONTACT_737]. 
3.4. Scientific Rationale for Study Design  
The aim  of this study is to determin e whether  avacopan is effective in subjects  with moderate to 
severe hidradenitis suppurativa. The placebo -controlled study design allows evaluation  of 
whether or not avacopan t reatment  will yield superior efficacy compared to placebo. A c ertain 
Avacopan (CCX168)   Protocol CL016_168 
[ADDRESS_788351] concomitant treatment for HS with doxycycline or 
minocycline.  
There is well -documented precedence of placebo -controlled trials in HS as previous ad alimumab 
Phase 2 and 3 studies were conducted as placebo-controlled studies. 
3.5. Rationale for Dose Selection  
Single doses of 1 mg up to 100 mg avacopan were studied in a Phase 1 study (CL001_168) in 48 healthy volunteers. Once daily doses of 1, 3, and 10 mg avacopan, and twice daily doses of 30 mg and 50 mg for up to 7 days were studied in the multiple dose period of the study. 
Doses from 3 mg up to 100 mg twice daily for 7 days were tested in 16 healthy volunteers in 
Phase 1 study CL007_168, and 30 mg (single dose and twice daily doses for 17 days) in [ADDRESS_788352] s were tested in both fed and fasted states at  doses up to 100 mg/day (CCX1101). 
All these avacopan doses were found to be safe in these studies. 
A dose of 30 mg avacopan twice daily given for 12 weeks was studied in clinical trial 
CL002_168 in subjects with AAV. This dose regimen was shown to be effective and well 
tolerated in study CL002_168. Doses of 10 mg and 30 mg avacopan twice daily given fo r 
12 weeks were studied in clinical trial CL003_168 in subjects with AAV and found to be well tolerated. Refer to the Investigator’s Brochure for detail s. 
A dose of 30 mg avacopan twice daily is being studied in a Phase 3 clinical trial in AAV (CL010_168). 
A dose of 30 mg avacopan twice daily has been selected for this study in HS based on experience 
with this dose regimen in subjects with AAV. This dose regimen is lower than the maximum 
dose regimen of 100 mg twice daily tested in study CL007_168. A dose regimen of 30 mg 
avacopan twice daily provides a trough (C
min) plasma avacopan concentration  of approximately 
204 ng/mL ; this concentration was shown to provide at least 95% C5aR blockade of blood 
neutrophils continuously throughout the day based on ex vivo C5a-induced CD11b upregulation 
assays conducted in whole blood samples obtained from subjects in Phase [ADDRESS_788353] 90% C5aR inhibition on blood neutrophils continuously 
throughout the day. 
Based on the favorable safety profile observed in the long-term toxicology studies (26 weeks in 
rats and 44 weeks in cynomolgus monkeys; see Investigat or’s Brochure ), and on the safety and 
tolerability results from the clinical trials conducted to date, [ADDRESS_788354] in this clinical trial.  
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 36 of 87 4. STUDY POPULATION  
Eligible adult subjects (at least 18 years of age) with moderate to severe hidradenitis suppurativa 
(Hurley Stage II or III) on standard -of-care therapy as specified by [CONTACT_596807] , are allowed to enter the study.  
4.1. Inclusion Criteria 
Subject s must meet all of the following inclusion criteria in order to enter the study:  
1. Aged at least 18 years of age;  
2. Clinical diagnosis of HS  (Hurley Stage II or III) , confirmed by a dermatologist, for at least 
[ADDRESS_788355] formation and scars ; Stage III disease is defined as 
having multiple interconnected tracts and abscesses across an entire anatomical area with 
diffuse or near diffuse involvement; 
3. HS lesions a re present in at least [ADDRESS_788356] anatomic areas (e .g., left and right axilla; or left 
axilla and left inguino -crural fold), one of which i s Hurley Stage II or Hurley Stage III;  
4. Inadequate or loss of response to a systemic course of antibiotics of [ADDRESS_788357] who has completed less than 90 days of antibiotic treatment may be allowed into the 
study upon discussion with the Medi cal Monitor if: 1) the subject has demonstrated 
intolerance to or contraindication for antibiotics to treat HS , or 2) it w as determined by [CONTACT_596798] [ADDRESS_788358] 
and a continued antibiotic therapy would therefore not be indicated.  
Inadequate or loss of response is defined if the following was obs erved despi[INVESTIGATOR_596767]: 
a. Progression of Hurley Stage (i.e., the Hurley Stage of at least one affected anatomic 
region progressed from I→II, II→III, or I→III);  
b. Subject required at least one intervention (e.g., incision and drainage or intralesional injection of corticosteroid); 
c. Subject experienced pain interfering with activities of daily living, with unsatisfactory relief from over -the-counter analgesics (e.g., ibuprofen or acetaminophen); 
d. Subject experienced pain requiring opi[INVESTIGATOR_2438], including tramadol; 
e. Subject experienced drainage interfering with activities of daily living (e.g., requires 
multiple dressing changes and/or changes of clothes daily); 
f. Subject experienced an increase in the number of anatomic regions affected by [CONTACT_156889];  
g. Subject experienced at least one new abscess or one new draining fistula.  
5. Must have at least 5 inflammatory nodules or abscesses at S creening;  
6. Must agree to use a topi[INVESTIGATOR_596768]; topi[INVESTIGATOR_596769], triclosan, benzoyl peroxide, or diluted 
bleach in bath water;  
7. Female subject s of childbearing potential may participate if adequate contraception is used 
during the study and for at least three months after study completion . Adequate contraception 
is defined as resulting in a failure rate of less than 1% per year (combined estrogen and 
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 37 of 87 progestogen [oral, intravaginal, or transdermal], or progestogen-only hormonal contraception 
where inhibition of ovulation is the primary mode of action [oral, injectable, or implantable], 
intra-uterine device, intra -uterine hormone releasing system, bilateral tubal occlusion, 
vasectomized partner, or true [absolute] sexual abstinence, i.e., in line with the preferred and 
usual lifestyle of the subject ). Male subjects with partners of childbearing potential may 
participate in the study if they had a vasectomy at least [ADDRESS_788359] three months after study completion.  In addition, a 
barrier method (i.e., condom, cervical cap, or diaphragm) must be used during intercourse 
between a male study subject and  a female partner  of childbearing potential; 
8. Willing and able to give written Informed Consent and to comply with the requirements of the study protocol; 
9. Judged by [CONTACT_596799], based on medical history, 
physical examination (including electrocardiogram [ECG]), and clinical laboratory 
assessments. Subject s with  clinical laboratory values that are outside of normal limits (other 
than those specified in the Exclusion Criteria) and/or with other abnormal clinical findings 
that are judged by [CONTACT_596808]. 
4.2. Exclusion Criteria  
Subject s will be excluded from study participation if any of the following criteria are met:  
1. Pregnant or breast -feeding;  
2. Any other skin disease that may interfere with the assessment of HS, such as a viral or fungal 
skin infection; 
3. Rapi[INVESTIGATOR_10480], expanding HS within 30 days prior to S creening;  
4. More than 20 drai ning fistulae at Screening ; 
5. Any anti -TNF -α treatment for HS or for other conditions prior to Day 1 visit will be 
prohibited. Exception: subjects who were previously treated with an anti- TNF -α drug and 
discontinued treatment >12 weeks prior to Day 1 visit are allowed for enrollment; 
6. Systemic antibiotics are generally excluded. Exception: subjects on systemic antibiotic 
treatment with doxycycline or mino cycline who have been on a stable dose for at least 
[ADDRESS_788360] been enrolled, no further enrollment of such subjects will be 
allowed ; 
7. Topi[INVESTIGATOR_596770] 14 days prior to D ay 1; 
8. Have started a topi[INVESTIGATOR_596771] 14 days prior to S creening or is 
anticipated to sta rt during the S creening period . Topi[INVESTIGATOR_596778] s started >14 days prior to Screening is allowed ; 
9. With the exception of permissible antibiotic treatment regimen s, have received a systemic 
medicine for HS  or with a potential therapeutic impact on HS , including systemic antibiotic  
therapy, biologics and other systemic therapi[INVESTIGATOR_596779], cyclosporine, retinoids, 
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 38 of 87 and fumaric acid esters, etc. , within a minimum of 30 days or 5 half- lives (whichever is 
longer) after taking the last dose ; 
10. Have received within 14 days prior to the Day 1  visit, or is  expected to require during the 
study,  oral or transdermal  opi[INVESTIGATOR_2467] (except for tramadol) for any reason ; non-opi[INVESTIGATOR_596780] a stable dose for at least 14 days prior to the Day 1  
visit (“ as needed ” dosing is not considered to be a stable dose); 
11. Currently taking a strong inducer of the cytochrome P450 3A4 (CYP3A4) enzyme, such as 
carbamazepi[INVESTIGATOR_050], phenobarbital, phenytoin, rifampin, or St. John's wort; 
12. Any of the following within 12 weeks prior to S creening: symptoma tic congestive heart 
failure requiring prescription medication, unstable angina (unless successfully treated with 
stent or by[CONTACT_4897]), clinically significant cardiac arrhythmia, myocardial infarction or 
stroke; 
13. History or presence of any form of cance r within the [ADDRESS_788361] carcinoma in situ that has been excised or resected completely and is without evidence of local recurrence or metastasis;  
14. Evidence of tuberculos is based on interferon γ release assay (IGRA ); 
15. HBV, HCV, or HIV viral screening test done at Screening or within 6 weeks prior to 
Screening showing evidence of active or chronic viral infection; 
16. Received a live vaccine within 4 weeks prior to Screening;  
17. WBC count less than 3500/μL, or neutrophil count less than 1500/μL, or lymphocyte count 
less than 500/µL before start of dosing; 
18. Evidence of hepatic disease: AST, ALT, alkaline phosphatase, or bilirubin >3 times the upper limit of normal before the start of dosing; 
19. Clinically significant abnormal electrocardiogram ( ECG ) during S creening  which, in the 
opi[INVESTIGATOR_689], may place the subject at unacceptable risk for study participation; 
20. Known hypersensitivity to avacopan or inactive ingredients of the avacopan capsules (including gelatin, polyethylene glycol, or macrogolglycero l hydroxystearate [EP] known 
also as polyoxyl 40 hydrogenated castor oil [ NF] or Cremophor
® RH 40 ); 
21. Participated in any clinical study of an investigational product within [ADDRESS_788362] dose; 
22. History or presence of any medical condition or disease which, in the opi[INVESTIGATOR_689], may place the subject  at unacceptab le risk for study participation . 
4.3. Screen Failures  
Screen failures are defined as subjects who consent to participate in the clinical trial but are not 
subsequently randomized to receive a study intervention or dosed with a ny study drug. A 
minimal set of screen failure information is required to ensure tra nsparent reporting of screen 
failure participants, to meet the Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to respond to queries from regulatory authorities. Minimal 
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 39 of 87 information includes demography, screen failure detai ls, eligibility criteria, and any serious 
adverse event (SAE).  
Individuals who do not meet the criteria for participation in this trial (screen failure) may 
potentially be rescreened. These cases need to be discussed with the Medical Monitor.  
4.4. Removal of Subject s from Therapy  
Investigators must clearly distinguish between discontinuation of study drug treatment and 
withdrawal from the study. Subject s who discontinue study drug treatment or who initiate 
medication changes (including those prohibited by [CONTACT_138773]) will not be automatically 
withdrawn from the study but all efforts must be made to continue to follow the subject s for all 
regularly scheduled visits. All safety and efficacy assessments should be completed.  
Investigators must take appropriate meas ures to make sure that subject s are motivated to comply 
with all requirements of the protocol in order to minimize the amount of missing data, including subjects who discontinue study treatment early or initiate medication changes (including those 
prohibited by [CONTACT_760]). If subjects are not followed, they should complete all safety and 
efficacy assessments  required for the Early Termination  visit. Investigators and their staff must 
take measures to actively maintain contact [CONTACT_596809] s in the study, such as telephone 
calls, texts,  or emails between visits, and offers for transportation support to visit the study site.  
Subject s may be w ithdrawn from the study for only one of the following reasons: 
1. Subject  withdrawal of consent to contribute additional outcome information; 
2. 
Subject non-compliance with dosing or diary completion;  
3. Loss to follow-up. 
Subject s may discontinue study drug treatment for any of the following reasons: 
1. Subject  withdraw al of consent ; 
2. The Investigator may discontinue study drug treatment  if, in his/her clinical judgment, it is in 
the best interest of the subject ; 
3. The Sponsor may request discontinuation of study drug treatment for safety reasons . If a 
subject  develops any of the following lab abnormal ities:  
If a subject develops ALT or AST >3x ULN, additional testing should be performed immediately 
and repeated in one week to assay for total an d fractionated  serum bilirubin concentration, serum 
albumin concentration, and prothrombin time or INR, in addition to repeat transaminase (ALT, 
AST) testing. In addition, i f a subject develops Grade 3 or greater increased hepatic 
transaminases (>5 times the upper limit of normal), or if a subject develops Grade 2 or greater 
increased transaminases (>3 times the upper limit of normal) with elevation of bilirubin to >[ADDRESS_788363] be permanently discontinued ( FDA Guidance 2009)  if any of the 
following markers of hepatic injury and/or impaired liver  synthetic function are observed, and 
cannot be attributed to a reversible etiology unrelated to study medication (e.g., cholelithiasis): 
• ALT or AST >8x ULN  
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 40 of 87 • ALT or AS T >5x ULN for more than 2 weeks 
• ALT or AST >3x ULN and (Total Bilirubin >2x ULN or INR >1.5) 
• ALT or AST >3x ULN with the appearance of fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%) 
If a subject develops Grade 3 or greater leukopenia (WBC count <2 x 109/L) or neutropenia 
(<1 x 109/L), or Grade 4 lymphopenia (<0.2 x 109/L), then study drug (avacopan or placebo) 
must be paused in this subject. In addition, if a subject develops Grade 2 leukopenia (WBC count 
<3 x 109/L, but ≥ 2 x 109/L), the subject must be followed closely for infection and for further 
significant reduction (reduction by [CONTACT_33018] 0.5 x 109/L or more, or to <2 x 109/L) in WBC 
count; if either occurs, then study drug must be paused in this subject. Study drug may be 
resumed only if the abnormal value returns to normal and the Investigator deems resumption to 
be appropriate. 
If a subject develops Grade 3 or worse CPK increase (>5 times the upper limit of normal), dosing 
with study drug must be paused in this subject . Study drug may be resumed only if the CPK 
returns to normal levels. 
Discontinuation of study medication due to inadequate or worsening response in Period 2:  
Unless prohibited for safety reasons, deemed inappropriate by [CONTACT_737], or subject 
withdraws consent, all subjects are allowed to enter Period 2. Subjects in Period 2 will discontinue taking study medication if at two consecutive protocol- specified visits  ≥14 days 
apart,  the AN count increases by [CONTACT_726] 50% compared to the AN count at Week 12. 
However, these subjects will be requested to remain in the study and to complete all study procedures if possible. In the event of early withdrawal from the study , the tests and evaluations 
listed for the Early Termination visit in Section  6.14 will be pe rformed , whenever possible. Data 
collected at this visit will be designated as an “Early Termination” visit in the electronic data capture ( EDC ) system . The Sponsor should be notified of all study drug treatment and study 
withdrawals in a timely manner.  
5. STUDY DRUG /TREATMENT 
5.1. Product Characteristics  
The study drug  consists of hard gelatin capsules containing 10 mg avacopan or placebo 
administered orally. Avacopan and placebo bottles and capsules will be identical in appearance. The capsules are manufactured u nder current good manufacturing practice. 
5.2. Doses and Regimens 
Subjects  will be asked to take 3 capsules of study drug orally with water and preferably with 
food every morning, and 3 capsules with water and  preferably with food in the evening 
approximately 1 2 hours after the morning dose, as instructed. Study drug will be taken for 
36 weeks (252 days ) continuously. Study drug will be dispensed as outline d in the Time and 
Even ts Table.  
Avacopan (CCX168)   Protocol CL016_168 
[ADDRESS_788364] udy center 
at each study visit for study drug compliance/ accountability  check . 
If a subject misses a dose, the missed dose should be taken as soon as possible. If it is close to 
the time for their next dose (within 3 hours), the missed dose should not be taken and the next 
dose should be taken at the regular time. 
On study visit days it is preferable that the subjects take the morning dose of study drug at the 
site following the collection of PK samples, if applicable to that visit.  
5.3. Drug Supp ly 
5.3.1. Packaging and Labeling 
Study drug will be packaged in treatment assignment -specific kits and provided to the study sites 
for dispensing. Capsules containing 10 mg avacopan  and/or identical placebo capsules will be 
packaged in plastic  bottles with child -resistant screw caps . Each kit will include 3 bottles.  Each 
bottle will contain 180 capsules with a label including , at minimum, the study number, bottle 
number, dosing instructions, storage instructions, and Sponsor name [CONTACT_3816]. 
5.3.2. Storage 
Study drug, both avacopan and placebo , capsules should be stored according to label 
instructions. Access should be restricted to pharmacy staff or to the designated responsible 
member of the Investigator’s staff, and to the study monitor. 
5.4. Blinding  
This study is double-blind. Blinding of the study will be achieved by [CONTACT_70731]: 
1. The study drug kits, bottles and capsule appearance for avacopan  and placebo wi ll be 
identical; 
2. Limited access to the randomization code : Sponsor personnel, study site personnel, stud y 
subject s, personnel responsible for study monitoring, and biostatisticians and data managers 
involved in data analysis of the study will remain blinded to treatment assignment for the 
duration of the study; 
3. While laboratory personnel conducting the PK as says will not be blinded to treatment 
assignment, unblinded avacopan  plasma concentration results will not be shared with the 
study site personnel or study staff who have direct contact [CONTACT_596810];  
4. Data that could potentially be unblinding, i.e., WBC and neutrophil count data within the 
normal range (i.e., values outside the normal range will be made available for safety 
monitoring) will not be made available to study site personnel, study subjects, personnel responsible for study monitoring, and biostatisticians and data managers during the study 
unless required for safety monitoring. Investigators, however, will be provided with safety 
laboratory data reports, flagging abnormally high and low values to make informed decisions regardi ng subject care.  
Treatment assignments for individual subject s in the blinded portion of the study will remain 
blinded to the study team,  Investigators, and subject s until after the study database has been 
Avacopan (CCX168)   Protocol CL016_168 
[ADDRESS_788365] ’s treatment assignment if it becomes medically necessary . An 
individual subject  treatment assignment may be unblinded only in the case of an adverse event 
that requires knowledge of the study drug  received by [CONTACT_596811]. The study monitor and Sponsor should be 
consulted or notified as soon as possible in the event that unblinding of an individual subject ’s 
treatment assignment occurs prior to study completion. 
When the last subject  has completed the double-blind treatment period, an unblinded analysis of 
the double-blind treatment period will be conducted. All data collected in the double-blind 
treatment per iod will be cleaned and locked before the analysis. To maintain the blinding of 
treatment assignment in the active treatment period, the Sponsor will designate a contract research organization (CRO) to conduct the analysis. The analysis results will be com municated 
to the Sponsor with aggregated data only (i.e., by [CONTACT_596812]). In the event it becomes  necessary to identify the treatment 
assignment for an individual subject for safety analy sis, the treatment assignment can be 
disclosed  on an individual basis. If occurred, these events will be documented. 
An external data monitoring committee (DMC) will be constituted for the study (see 
Section  10.1.6). The DMC members will review data periodically over the course of the study in 
an unblinded manner. The membership and the primary responsibilities of the DMC  will be 
defined in a charter that  will also provide procedures for data review, documentation, and 
communication of recommendations. 
5.5. Drug Accountability 
The Investigator or designee is responsible for maintaining complete accountability including  
dates and quantities of study product(s) received, accurate inventory on an ongoing basis as well 
as dispensation and returned medication records. Periodically throughout the study, a Sponsor 
representative, usually the study monitor, will verify and inventory the used, unused, and 
partially used study drug. The Investigator or designee must retain all unu sed and/or expi[INVESTIGATOR_596781]. 
With Sponsor approval following drug accountability, unused study drug can be destroyed per 
site SOP or policy. Unused study drug may  also be returned to the S ponsor or its designee for 
destruction with appropriate documentation. The document ation  of such disposition/destruction 
should be maintained in the pharmacy files to be reviewed by a Sponsor representative. 
At the termination of the study, a final drug accountability review and reconciliation must be 
performed and any discrepancies must be investigated and their resolution documented. 
Please refer to the Study Pharmacy Manual for further instruction regarding study drug 
receiving, handling, storage and re turn/destruction . 
5.6. Treatment Compliance  
The avacopan  and placebo capsules will be self -administered by [CONTACT_596813] s. Th e 
first dose of study drug on Day [ADDRESS_788366] s 
will be provided with dosing instructions at the start of the study and will be encouraged by 
[CONTACT_596814] g to the instructions for the duration of the 
Avacopan (CCX168)   Protocol CL016_168 
[ADDRESS_788367]  compliance. Any events of non-compliance to the protocol will be documented in 
the study records. 
5.7. Concomitant Therapy  and Restrictions  
No new treatment for HS (other than the study drug) may be introduced during the study period 
with the exceptions as outlined below. 
All concomitant medications taken during the course of the study must be recorded meticulously 
on the concomi tant medication pages in the EDC . 
Anti-  TNF -α Therapy, Systemic or Other Treatments  with Potential Impact on HS : 
Concomitant anti -TNF -α treatment during the trial is  prohibited. Subjects  who were previously 
treated with any anti -TNF -α drug and discontinued treatment >12 weeks prior to D ay 1 visit 
would be allowed for enrollment. 
Anti-TNF -α agents comprise five different FDA-approved drugs: adalimumab (Humira®), 
infliximab (Remicade®), entanercept (Enbrel®), golimumab (Simponi®), and certolizumab 
(Cimzia®). Of these anti -TNF -α agents, adalimumab, golimumab, and certolizumab share the 
longest mean terminal half -lives of [ADDRESS_788368] 12 weeks (which provides a washout period 
of over 5 times the half- life of any anti-TNF -α agent) . 
With the exception of permissible antibiotic treatment regimens, systemic or other treatments  
with a potential therapeutic impact on HS, including systemic antibiotic therapy, biologics and 
other systemic therapi[INVESTIGATOR_596779], cyclosporine, retinoids, and fumaric acid esters, 
etc., are prohibited.  
Antibiotic T herapy : Concomitant use of oral antibiotic therapy for treatment of HS is generally 
not allowed. Systemic antibiotics (doxycycline or minocycline only) for the treatment of HS are 
permissible only for those subjects whose randomization was appropriately st ratified for 
antibiotic use (see Section  3.1 Stratification and Randomization). During the study, the dose(s) of 
these drugs for the treatment of HS may not be increased. A systemic antibiotic must not be started for the treatment of HS during the course of the trial (treatment for a condition other than 
HS is allowed).  However, the Investigator s will be allowed to reduce the dose(s) or discontinue 
these ongoing antibiotic treatments during the study. Any dose changes in these treatments 
during the study must be recorded in the EDC  system . 
Antibiotic rescue  medication may be initiated  at Week [ADDRESS_788369] experiences an 
increase in their AN count such that the total count is greater  than  or equal  to 150% of their 
baseline AN count. For example, if a subject has a baseline (= Day 1) AN count of 15, antibiotic rescue therapy may be allowed with a minimum AN count of 23 (1.5 x 15 = 22.5) at Week 4 or 8. 
Avacopan (CCX168)   Protocol CL016_168 
[ADDRESS_788370] be captured in the source document and on the appropriate eCRF. 
Antiseptic Therapy : All subjects must use a top ical antiseptic daily over the course of the study; 
topi[INVESTIGATOR_596782], triclosan, benzoyl peroxide, 
or dilute bleach in bath water. Wound Care : Concomitant use of wound care dressings on HS wounds is allow ed. 
Lesion Intervention : In the event that an acutely painful lesion occurs that requires an immediate 
intervention, physicians will have the option to perform protocol-allowed interventions. All 
study visit evaluations must occur before any interventions are performed. Any lesion that 
undergoes an intervention will be documented in the source. The site will be required to count 
any lesion that undergoes an intervention as permanently present from the date of the intervention, and must account for it in the source and on the appropriate eCRF. 
Lesions that receive lesion  interventions will be reported as adverse events. 
Only two types of interventions are allowed: injection with intralesional triamcinolone acetonide 
suspension (i ntralesional Kenalog
 rescue injections , i.e., triamcinolone acetonide, [ADDRESS_788371] within a period no longer than 1 week) and incision and drainage. 
If incision and drainage is performed, the required over-the-counter antiseptic wash should 
continue to be used. New systemic and topi[INVESTIGATOR_505938] (including antibiotics), are prohibited. Concomitant use of wound care dressings is allowed . 
Subjects should continue using any allowed ongoing oral and topi[INVESTIGATOR_319848]. 
During Period 1, a total of two protocol-allowed interventions are permissible . An intervention 
can occur on maximally two different lesions at the same visit or on the same  lesion at two 
different study visits. The same lesion cannot be treated two times at the  same visit. If a subject 
requires more than two interventions within the first [ADDRESS_788372] discontinue taking 
study medication. However, these subjects will be requested to remain in the study and to complete all study procedures if possible.  
Analgesic Therapy : Subjects may receive non -opi[INVESTIGATOR_596783]. Any dose changes need to be recorded in the EDC. Oral and transdermal opi[INVESTIGATOR_2467] (except for tramadol) for any reason  are disallowed.  
CYP3A4 Metabolism : Drugs that are strong inducers of the CYP3A4  enzyme, such as 
carbamazepi[INVESTIGATOR_050], phenobarbital, phenytoin, rifampin or St. John’s wort are prohibited during the study because these drugs may substantially reduce the plasma concentrations of avacopan and reduce its effectiveness.  
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 45 of 87 Substances that are strong inhibitors of CYP3A4, such as boceprevir, clarithromycin, conivaptan, 
indinavir, itraconazole, ketoconazole, lopi[INVESTIGATOR_054]/ritonavir, mibefradil, nefazodone, nelfinavir, 
posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, and voriconazole, and grapefruit juice should be avoided during the study, because these may modestly increase (~2- fold) t he 
plasma concentrations of avacopan. However, these are not absolutely contra- indicated. If these 
must be used concomitantly with avacopan, subjects should be monitored carefully for any untoward side effects. 
All concomitant medications taken during the course of the study must be recorded meticulously 
on the concomi tant medication pages in the EDC . 
6. STUDY PROCEDURES   
6.1. Screening and Enrollment  
Informed consent must be obtained prior to performance of any study- specific tests or 
evaluations. Screening should occur within [ADDRESS_788373] s will undergo the following evaluations to determine their eligibility for 
study participation: 
• Recording of demographic data and relevant medical history  in the EDC; 
• Recording of all prior medications and treatment s for HS from diagnosis to S creening in 
the EDC;  
• Recording of all other concomitant medications on the S creening day(s) in the EDC , 
including alcohol intake, recreational drug use, non-prescription medications, herbal 
preparations or special diets ; 
• A physical examination will be performed  (see Section  7.2.1) ; body weight and  height 
will be measured ; 
• Vital signs will be obtained as detailed in Section  7.2.1; temperature, sitting blood 
pressure, and heart rate will be measured after at least [ADDRESS_788374];  
• Serum pregnancy test (in women of childbearing potential); 
• Virology assessments as detailed in Section  7.2.2, unless done within 6 weeks prior to 
Screening;  
• Tuberculosis exclusion based on interferon γ release assay (IGRA); 
• 12-lead ECG  to exclude any clinically significant findings ; 
• Serum chemistry and hematology tests according to Section  7.2.2;  
• A urine sample will be collected for urinal ysis (see Section  7.2.2) ; 
• The anatomic location and number of HS inflammatory nodules, abscesses, fistulae, and hypertrophic scars and the Hurley Stage of HS will be recorded ; 
• Any pre -treatment  adverse events (occurring during the Screening visit) will be recorded . 
Avacopan (CCX168)   Protocol CL016_168 
[ADDRESS_788375] ’s 
condition. Results from the prior tests must be recorded in the EDC. 
After all Screening procedures have been completed and the subject  satisfies all eligibility 
criteria: 
• The study schedule will be discussed with the subject  and the schedule will be provided 
to the subject  to ensure compliance with the study visits . 
• Subjects will be issued a daily diary on Day -[ADDRESS_788376] 
skin pain in th e daily diar y and will be asked to start recording their skin pain starting that 
day (one week prior to the Day 1 visit). 
6.2. Study Day [ADDRESS_788377] dose of study drug: 
• Stratification and randomization  in the I RT system ; 
• A physical examination  including body weight; 
• Vital signs (temperature, sitting blood pressure , heart rate)  after at least [ADDRESS_788378] ; 
• Urine  pregnancy test  (in women of childbearing potential); 
• Blood samples will be collected for serum chemistry, hematology, serum pregnancy test 
(in women of childbearing potential), and PK measurements;  
• Biomarker plasma sample will be collected (see Section  7.4); 
• The date and time of collection of the PK sample will be recorded ; 
• A urine sample will be collected  for urinalysis;  
• The anatomic location and number of HS inflammatory nodules, abscesses, fistulae, and 
hypertrophic scars will be recorded;  
• Lesions will be selected and baseline photography will be completed ; 
• Items for the Sartorius and modified Sartorius scores will be collected  (see Section  7.1.2) ; 
• IHS4 score will be calculated (se e Section  7.1.3) ; 
• The Investigator will complete the HS -PGA; 
• Study personnel will record health-economic information; 
• Subject s will be asked to complete the SF -36 v2, EQ -5D- 5L, HiSQOL, DLQI , and 
WPAI:SHP forms ; 
• Compliance with daily r ecording of skin pain in daily diary starting one week prior to 
Day 1 will be checked  and retraining provided, if necessary; 
• Any pre -treatment adverse events (from time of the Screening visit) will be recorded . 
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 47 of 87 Thereafter, the following procedures will be performed: 
• Study drug will be provided to the subject  with dosing instructions (see Section  5.2); 
• The subject  will be asked to take the first dose of study drug  while at the study center;  
• The time of the dosing of study drug will be recorded;  
• Any changes in concomitant medication use will be recorded , including alcohol intake, 
recreational drug use, non -prescript ion medications, herbal preparations or special diets; 
• Any post-dosing adverse events will be recorded; 
• After all study procedures have been completed, the subject  will be reminded to: 
− Record severity of skin pain and study drug dosing in daily diary; 
− Come to the study center for the Week 2  study visit;  
− Store the study drug  in a cool and dry place according to label instructions for the 
duration of the study; 
− Take the study drug, as instructed . On study visit days, it is preferable that the 
subjects tak e the morning dose of study drug  at the site following the collection of PK 
samples, if applicable to that visit, and  
− Continue taking all their other concomitant medications as usual. 
6.3. Study Week 2 (Day 15) 
The Study Week [ADDRESS_788379] occur within ± 2 day s of the scheduled date. During this visit, the 
following study procedures will be performed: 
• A physical examination  including body weight; 
• Vital signs (temperature, sitting blood pressure , heart rate)  after at least [ADDRESS_788380] ; 
• Blood samples will be collected for shipment to the central laboratory for serum 
chemistry, hematology, and PK measurements ; the date and time of collection of the PK 
sample will be recorded ; 
• The date and time of the last dose of study drug prior to collection of the PK sample will 
be recorded;  
• If the subject has not yet taken the morning dose of study drug for this day, the subject 
will be asked to take the dose; 
• The anatomic location and number of HS inflammatory nodules, abscesses, fistulae, and 
hypertrophic s cars will be recorded;  
• Follow-up photography of lesions will be completed; 
• Compliance with daily recording of skin pain  and drug dosing in diaries will be checked 
and re -training provided if necessary;  
• Items for the Sartorius and modified Sartorius scores will be colle cted;  
• IHS4 score will be calculated;  
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 48 of 87 • The Investigator will complete the HS -PGA;  
• Study personnel will record health -economic information ; 
• The study site personnel will make sure the subject is taking the study drug as instructed;  
• Any changes in concomitant medication use will be recorded , including alcohol intake, 
recreational drug use, non -prescription medications, herbal preparations or speci al diet s; 
• Any adverse events will be recorded;  
• After all study procedures have been completed, the subject  will be reminded to: 
− Record severity of skin pain and study drug dosing in daily diary; 
− Come to the study center for the Week 4 study visit;  
− Store th e study drug in a cool and dry place according to label instructions for the 
duration of the study; 
− Take the study drug as instructed . On study visit days, it is preferable that the subjects 
take the morning dose of study drug at the site following the collection of PK 
samples, if applicable to that visit, and  
− Continue taking all their other c oncomitant medications as usual.  
6.4. Study Week  4 (Day 29)  
The Study Week [ADDRESS_788381] occur within ± 2 day s of the scheduled date. During this visit, the 
following study procedures will be performed: 
• A physical examination  including body weight; 
• Vital signs (temperature, sitting blood pressure , heart rate)  after at least [ADDRESS_788382] ; 
• Blood samples will be collected for serum chemistry, hematology, serum pregnancy tes t 
(in women of childbearing potential), and PK measurements ; the date and time of 
collection of the PK sample will be recorded;  
• The date and time of the last dose of study drug  prior to collection of the PK sample will 
be recorded;  
• If the subject  has not yet taken the morning dose of study drug for this day, the subject  
will be asked to take the dose; 
• A urine sample will be collected  for urinalysis ; 
• The anatomic location and number of HS inflammatory nodules, abscesses, fistulae, and hypertrophic s cars will be recorded;  
• Follow-up photography of lesions will be completed; 
• Compliance with daily recording of skin pain and study drug dosing in diaries will be checked and retraining provided, if necessary;  
• Items for the  Sartorius and  modified Sartorius scores wil l be collected;  
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 49 of 87 • IHS4 score will be calculated;  
• The Investigator will complete the HS -PGA; 
• Study personnel will record health-economic information; 
• Subjects will be asked to complete the SF -36 v2, EQ-5D- 5L, HiSQOL, DLQI , and 
WPAI:SHP forms;  
• The study site personnel will make sure the subject is taking the study drug as instructed; 
• Any changes in concomitant medication use will be recorded , including alcohol intake, 
recreational drug use, non -prescription medications, herbal preparations or special diets; 
• Any adverse events will be recorded;  
• After all study procedures have been completed, the subject  will be reminded to: 
− Record severity of skin pain and study drug dosing in daily diary; 
− Come to the study center for the Week 8 study visit;  
− Store the study drug in a cool and dry place according to label instructions for the 
duration of the study; 
− Take the study drug as instructed . On study visit days, it is preferable that the subjects 
take the morning dose of study drug at the site following the collection of PK  
samples, if applicable to that visit; and  
− Continue taking all their other concomitant medications as usual. 
6.5. Study Week 8 (Day 57) 
The Study Week [ADDRESS_788383] occur within ± 2 days of the scheduled date. During this visit, the 
following study procedures wi ll be performed:  
• A physical examination  including body weight; 
• Vital signs (temperature, sitting blood pressure , heart rate)  after at least [ADDRESS_788384] ; 
• Blood samples will be collected for serum chemistry, hematology, serum pregnancy test 
(in women of childbearing potential), and PK measurements ; the date and time of 
collection of the PK sample will be recorded;  
• The date and time of the last dose of study drug  prior to collection of the PK sample will 
be recorded;  
• If the subject  has not yet taken the morning dose of study drug for this day, the subject  
will be asked to take the dose; 
• A urine sample will be collected  for urinalysis;  
• The anatomic location and number of HS inflammatory nodules, abscesses, fistulae, and 
hypertrophic scars  will be recorded;  
• Follow-up photography of lesions will be completed; 
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 50 of 87 • Compliance with daily recording of pain and study drug dosing in diaries will be checked 
and retraining provided, if necessary;  
• Items for the  Sartorius and  modified Sartorius scores will be collected ; 
• IHS4 score will be calculated;  
• The Investigator will complete the HS -PGA;  
• Study personnel will record health-economic information ; 
• The s tudy site personnel will make sure the subject is taking the study drug as instructed 
and that the subject has adequate st udy drug for dosing until the following visit; 
• Any changes in concomitant medication use will be recorded , including alcohol intake, 
recreational drug use, non -prescription medications, herbal preparations or special diets; 
• Any adverse events will be recor ded; 
• After all study procedures have been completed, the subject  will be reminded to: 
− Record severity of skin pain and study drug administration in daily diary; 
− Come to the study center for the Week 12  study visit;  
− Store the study drug in a cool and dry place according to label instructions for the 
duration of the study; 
− Take the study drug as instructed . On study visit days, it is preferable that the subjects 
take the morning dose of study drug at the site following the collection of PK samples, if applicable to that visit; and  
− Continue taking all their other concomitant medications as usual. 
6.6. Study Week 1 2 (Day 85) 
The Study Week [ADDRESS_788385] occur within ± 2 days of the scheduled date. During this visit, the 
following study procedures will be performed: 
• A physical examination  including body weight; 
• Vital signs (temperature, sitting blood pressure , heart rate)  after at least [ADDRESS_788386] ; 
• Blood samples will be collected for serum chemistry, hematology, serum pregnancy test 
(in women of childbearing pot ential), and PK measurements ; the date and time of 
collection of the PK sample will be recorded;  
• Biomarker plasma sample will be collected;  
• A 12-lead ECG  will be taken to exclude any clinically significant findings;  
• The date and time of the last dose of study drug  prior to collection of the PK sample will 
be recorded;  
• If the subject  has not yet taken the morning dose of study drug for this day, the subject  
will be asked to take the dose;  
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 51 of 87 • A urine sample will be collected  for urinalysis;  
• The anatomic locati on and number of HS inflammatory nodules, abscesses, fistulae, and 
hypertrophic s cars will be recorded;  
• Follow-up photography of lesions will be completed;  
• Compliance with daily recording of pain in diaries will be checked and re -training 
provided, if nec essary;  
• Items for the Sartorius and modified Sartorius scores will be collected;  
• IHS4 score will be calculated;  
• The Investigator will complete the HS -PGA; 
• Study personnel will record health-economic information ; 
• Subjects will be asked to complete the SF -36 v2, EQ-5D-5L, HiSQOL, DLQI, and 
WPAI:SHP forms;  
• Drug accountability will be performed ; the returned bottles of study drug will be checked 
to make sure the subject is taking the study drug as instructed; 
• Study drug  will be dispensed. Note: At this visit, s ubjects who were assigned to placebo 
arm will be re -randomized to receive 10 mg or 30 mg avacopan  twice a day ; 
• Any changes in concomitant medication use will be recorded , including alcohol intake, 
recreational drug use, non -prescription medications, herbal preparations or special diets; 
• Any adverse events will be recorded;  
• After all study procedures have been completed, the subject  will be reminded to: 
− Record severity of skin pain and study drug dosing in daily diary; 
− Come to the study center for the Week 1 6 study visit;  
− Store the study drug in a cool and dry place according to label instructions for the 
duration of the study; 
− Take the study drug as instructed . On study visit days, it is preferable that the subjects 
take the morning dose of study drug at the site following the collection of PK 
samples, if applicable to that visit; and  
− Continue taking all their other concomitant medications as usual. 
6.7. Study Week 16 (Day 113)  
The Study Week [ADDRESS_788387] occur within ± 2 days of the scheduled date. During this visit, the 
following study procedures will be performed: 
• A physical examination  including body weight; 
• Vital signs (temperature, sitting blood pressure , heart rate)  after at least [ADDRESS_788388] ; 
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 52 of 87 • Blood samples will be collected for serum chemistry, hema tology, serum pregnancy test 
(in women of childbearing potential), and PK measurements ; the date and time of 
collection of the PK sample will be recorded;  
• The date and time of the last dose of study drug prior to collection of the PK sample will 
be recorded; 
• If the subject  has not yet taken the morning dose of study drug for this day, the subject  
will be asked to take the dose; 
• A urine sample will be collected  for urinalysis;  
• The anatomic location and number of HS inflammatory nodules, abscesses, fistulae, and 
hypertrophic s cars will be recorded;  
• Follow-up photography of lesions will be completed; 
• Compliance with daily recording of pain and study drug dosing in diaries will be checked and re -training provided, if necessary;  
• Items for the Sartorius and modified Sartorius scores will be collected;  
• IHS4 score will be calculated;  
• The Investigator will complete the HS -PGA;  
• Study per sonnel will record health-economic information ; 
• Subjects will be asked to complete the SF -36 v2, EQ-5D- 5L, HiSQOL, DLQI,  and 
WPAI:SHP forms;  
• The s tudy site personnel will make sure the subject is takin g the study drug as instructed; 
• Any changes in concomitant medication use will be recorded , including alcohol intake, 
recreational drug use, non -prescription medications, herbal preparations or special diet s; 
• Any adverse events will be recorded;  
• After all study procedures have been completed, the subject  will be reminded to: 
− Record severity of skin pain and study drug dosing in daily diary; 
− Come to the study center for the Week 20  study vis it; 
− Store the study drug in a cool and dry place according to label instructions for the 
duration of the study; 
− Take the study drug as instructed . On study visit days, it is preferable that the subjects 
take the morning dose of study drug at the site follo wing the collection of PK 
samples, if applicable to that visit; and  
− Continue taking all their other concomitant medications as usual. 
6.8. Study Week 20 (Day 141)  
The Study Week [ADDRESS_788389] occur within ± 2 days of the scheduled date. During this visit, the 
following study procedures will be performed: 
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 53 of 87 • A physical examination  including body weight; 
• Vital signs (temperature, sitting blood pressure , heart rate)  after at least [ADDRESS_788390] ; 
• Blood samples will be collected for serum chemistry, hematology, serum pregnancy test 
(in women of childbearing potential), and PK measurements ; the date and time of 
collection of the PK sample will be recorded;  
• The date and time of the last dose of study drug prior to collection of the PK sample will 
be recorded;  
• If the subject  has not yet taken the morning dose of study drug for this day, the subject  
will be asked to take the dose; 
• A urine sample will be collected  for urinalysis;  
• The anatomic location and number of HS inflammatory nodules, abscesses, fistulae, and 
hypertro phic s cars will be recorded;  
• Follow-up photography of lesions will be completed; 
• Compliance with daily recording of pain in diaries will be checked and re -training 
provided, if necessary;  
• Items for the Sartorius and modified Sartorius scores will be collec ted; 
• IHS4 score will be calculated;  
• The Investigator will complete the HS -PGA;  
• Study personnel will record health-economic information ; 
• The s tudy site personnel will make sure the subject is taking the study drug as instructed 
and that the subject has adeq uate study drug for dosing until the following visit;  
• Any changes in concomitant medication use will be recorded , including alcohol intake, 
recreational drug use, non -prescription medications, herbal preparations or special diets; 
• Any adverse events will be recorded;  
• After all study procedures have been completed, the subject  will be reminded to: 
− Record severity of skin pain and study drug dosing in daily diary; 
− Come to the study center for the Week 24 study visit;  
− Store the study drug in a cool and dry place according to label instructions for the 
duration of the study; 
− Take the study drug as instructed . On study visit days, it is preferable that the subjects 
take the morning dose of study drug at the site following the collection of PK samples, if applicab le to that visit; and  
− Continue taking all their other concomitant medications as usual. 
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 54 of 87 6.9. Study Week 24 (Day 169)  
The Study Week [ADDRESS_788391] occur within ± 2 days of the scheduled date. During this visit, the 
following study procedures will be performed: 
• A physical examination including body weight; 
• Vital signs (temperature, sitting blood pressure, heart rate) after at least [ADDRESS_788392]; 
• Blood samples will be collected for serum chemistry, hematology , and serum  pregnancy 
test (in women of childbearing potential); 
• Drug accountability will be performed ; the returned bottle s of study drug will be checked 
to make sure the subject is taking the study drug as instructed; 
• A urine sample will be collected  for urinalysis;  
• The anatomic location and number of HS inflammatory nodules, abscesses, fistulae, and hypertrophic scars will be recorded; 
• Follow-up photography of lesions will be completed; 
• Compliance with  daily recording of pain in diar y will be checked and re- training 
provided, if necessary; 
• Study drug will be dispensed; 
• Items for the Sartorius and modified Sartorius scores will be collected;  
• IHS4 score will be calculated;  
• The Investigator will complete the HS -PGA;  
• Study personnel will record health- economic information ; 
• Any changes in concomitant medication  use will be recorded , including alcohol intake, 
recreational drug use, non -prescription medications, herbal preparations or special diets; 
• Any adverse events will be recorded;  
• After all study procedures have been completed, the subject will be reminded to: 
− Record severity of skin pain and study drug dosing in daily diary; 
− Come to the study center for the Week 28 study visit; 
− Store the study drug in a cool and dry place according to label instructions for the 
duration of the study; 
− Take the study drug as in structed. On study visit days, it is preferable that the subjects 
take the morning dose of study drug at the site following the collection of PK 
samples, if applicable to that visit; and  
− Continue taking all other concomitant medications as usual. 
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 55 of 87 6.10. Study Wee k 28 (Day 197) 
The Study Week [ADDRESS_788393] occur within ± 2 days of the scheduled date. During this visit, the 
following study procedures will be performed: 
• A physical examination  including body weight; 
• Vital signs (temperature, sitting blood pressure, he art rate)  after at least [ADDRESS_788394] ; 
• Blood samples will be collected for serum chemistry, hematology, serum pregnancy test 
(in women of childbearing potential), and PK measurements ; the date and time of 
collection of the PK sample will be recorded;  
• The date and time of the last dose of study drug  prior to collection of the PK sample will 
be recorded;  
• If the subject  has not yet taken the morning dose of study drug for this day, the subject  
will be asked to take the dose; 
• A urine sample will be collected  for urinalysis;  
• The anatomic location and number of HS inflammatory nodules, abscesses, fistulae, and 
hypertrophic s cars will be recorded;  
• Follow-up photography of lesions will be completed; 
• Compliance with daily recording of pain and study drug dosing in diaries will be checked and re -training provided, if necessary;  
• Items for the  Sartorius and  modified Sartorius scores will be collected;  
• IHS4 score will be calculated;  
• The Investigator will complete the HS -PGA;  
• Study personnel will record health-economi c information ; 
• Subjects will be asked to complete the SF -36 v2, EQ-5D- 5L, HiSQOL, DLQI,  and 
WPAI:SHP forms;  
• The s tudy site personnel will make sure the subject is taking the study drug as instructed; 
• Any changes in concomitant medication use will be recorded , including alcohol intake, 
recreational drug use, non -prescription medications, herbal preparations or special diets; 
• Any adverse events will be recorded;  
• After all study procedures have been completed, the subject  will be reminded to: 
− Record severity o f skin pain and study drug dosing in daily diary; 
− Come to the study center for the Week 32 study visit;  
− Store the study drug in a cool and dry place according to label instructions for the 
duration of the study; 
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 56 of 87 − Take the study drug as instructed . On study visit days, it is preferable that the subjects 
take the morning dose of study drug at the site following the collection of PK 
samples, if applicable to that visit; and  
− Continue taking all their other concomitant medications as usual. 
6.11. Study Week 32 (Day 225) 
The Study Week [ADDRESS_788395] occur within ± 2 days of the scheduled date. During this visit, the following study procedures will be performed: 
• A physical examination including body weight; 
• Vital signs (temperature, sitting blood pressure, heart rate) after at least [ADDRESS_788396]; 
• Blood samples will be collected for serum chemistry, hematology,  and serum pregnancy 
test (in women of childbearing potential); 
• A urine sample will be collected  for urinalysis;  
• The anatomic location and number of HS inflammatory nodules, abscesses, fistulae, and 
hypertrophic scars will be recorded; 
• Follow-up photography of lesions will be completed; 
• Compliance with daily recording of pain in dairy will be checked and re- training 
provided, if necessary; 
• Items for the Sartorius and modified Sartorius scores will be collected;  
• IHS4 score will be calculated;  
• The Investigator will complete the HS -PGA;  
• The s tudy site personnel will make sure the subject is taking the study drug as instructed  
and that the subject has adequate study dr ug for dosing until the following visit; 
• Study personnel will record health-economic information ; 
• Any changes in concomitant medication use will be recorded , including alcohol intake, 
recreational drug use, non -prescription medications, herbal preparations or special diet s; 
• Any adverse events will be recorded;  
• After all study procedures have been completed, the subject will be reminded to: 
− Record severity of skin pain and study drug dosing in daily diary; 
− Come to the study center for the Week 36 study visit; 
− Store the study drug in a cool and dry place according to label instructions for the 
duration of the study; 
− Take the study drug as instructed. On study visit days, it is preferable that the subjects 
take the morning dose of study drug at the site following the collection of PK samples, if applicable to that visit; and  
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 57 of 87 − Continue taking all their other concomitant medications as usual. 
6.12. Study Week 36 (Day 253) 
The Study Week [ADDRESS_788397] occur within ± 2 days of the scheduled date. During this visit, the 
following study procedures will be performed: 
• A physical examination  including body weight; 
• Vital signs (temperature, sitting blood pressure , heart rate)  after at least [ADDRESS_788398] ; 
• Blood samples will be collected for serum chemistry, hematology, serum pregnancy test 
(in women of childbearing potential), and PK measurements ; the date and time of 
collection of the PK sample will be recorded;  
• Biomarker plasma sample will be collected;  
• The date and time of the last dose of study drug  prior to collection of the PK sample will 
be recorded;  
• A urine sample will be collected  for urinalysis;  
• The anatomic location and number of HS inflammatory nodules, abscesses, fistulae, and 
hypertrophic s cars will be recorded;  
• Follow-up photography of lesions will be completed; 
• Compliance with daily recording of pain and study drug dosing in diaries will be checked and re -training provided, if necessary;  
• Items for the Sartorius and modified Sartorius scores will be collected;  
• IHS4 score will be calculated;  
• The Investigator will complete the HS -PGA;  
• Study personnel will record health-economic information ; 
• Subjects will be asked to complete the SF -36 v2, EQ-5D-5L, HiSQOL, DLQI, and 
WPAI:SHP forms;  
• Drug accountability will be performed on the returned bottle(s) of study drug; 
• Any cha nges in concomitant medication use will be recorded , including alcohol intake, 
recreational drug use, non -prescription medications, herbal preparations or special diets; 
• Any adverse events will be recorded;  
• After all study procedures have been completed, t he subject  will be reminded to: 
− Record severity of skin pain in daily diary; 
− Come to the study center for the Week 44 study visit; and  
− Continue taking all their other concomitant medications as usual. 
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 58 of 87 6.13. Study Week 44  (Day 309 ) 
The Study Week 44 (follow-up) visit must occur within ± 4 days of the scheduled date. During 
this visit, the following  study procedures will be performed: 
• A physical examination  including body weight; 
• Vital signs (temperature, sitting blood pressure , heart rate)  after at least [ADDRESS_788399] ; 
• A 12-lead ECG  will be taken  to exclude any clinically significant findings;  
• Blood samples will be collected for serum chemistry, hematology  and PK measurements ; 
the date and time of collection of the PK sample will be recorded; 
• A urine sample will be collected  for urinalysis;  
• The anatomic location and number of HS inflammatory nodules, abscesses, fistulae, and 
hypertrophic s cars will be recorded;  
• Follow-up photography of lesions will be completed; 
• Items for the Sartorius and modified Sartorius score s will be collected;  
• IHS4 score will be calculated;  
• The Investigator will complete the HS -PGA;  
• Study personnel will record health-economic information ; 
• Subjects will be asked to complete the SF -36 v2, EQ-5D-5L, HiSQOL, DLQI, and 
WPAI:SHP forms;  
• The compl eted daily diary will be collected ; 
• Any changes in concomitant medication use will be recorded , including alcohol intake, 
recreational drug use, non -prescription medications, herbal preparations or special diets; 
• Any adverse events will be recorded;  
• After all study procedures have been completed, the subject  will exit the study. 
6.14. Early Termination Visit  
If a subject  will be withdrawn early from the study, the following termination procedures must 
be completed whenever possible: 
• A physical examination  includi ng body weight; 
• Vital signs (temperature, sitting blood pressure , heart rate)  after at least [ADDRESS_788400] ; 
• A 12 -lead ECG will be taken to exclude any clinically significant findings;  
• Blood samples for serum chemistry, hematology, and serum pregnancy test (in women of 
childbearing potential) , and PK measurements; the date and time of collection of the PK 
sample will be recorded;  
• Biomarker plasma sample will be collected;  
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 59 of 87 • A urine sample will be collected  for urin alysis ; 
• The anatomic location and number of HS inflammatory nodules, abscesses, fistulae, and 
hypertrophic scars will be recorded;  
• Follow-up photography of lesions will be completed; 
• Items for the Sartorius and modified Sartorius scores will be collected  if the prior visit 
where this assessment was made was more than 2 weeks before ; 
• IHS4 score will be calculated;  
• The Investigator will complete the HS -PGA, if the prior visit where these assessments 
were made was more than 2 weeks before;  
• Study personnel will record health -economic information ; 
• Subje cts will be asked to complete the SF-36 v2, EQ -5D- 5L, HiSQOL, DLQI, and 
WPAI:SHP forms, if the prior visit where these assessments were made was more than 2 weeks before;  
• Drug accountability will be performed on the returned bottles of study drug; 
• Completed daily diary will be collected ; 
• Any changes in concomitant medication use will be recorded , including alcohol intake, 
recreational drug use, non -prescription medications, herbal preparations or special diets; 
• Any adverse events will be recorded . 
7. STUDY ASS ESSMENTS 
7.1. Efficacy Assessments  
7.1.1. Location and Extent of Hidradenitis Suppurativa Assessment  
The location and extent of HS will be assessed at visits in the Time and Events Table by 
[CONTACT_596815](s) of the disease, as well as the number of HS  inflammatory 
nodules, abscesses, fistulae, and hypertrophic scars in each of the location s in the EDC. All study 
Investigators will receive study specific training to assess HS lesions. 
The same Investigator should assess the lesions at each visit to ass ure consistency. Study sites 
should schedule all visits for the same subject such that the same Investigator is available to assess the lesions of that subject.  
The information regarding location and extent of HS involvement will be used to determine the 
Hurley Stage and also to calculate the HiSCR at post -baseline visits. The HiSCR will be 
calculated programmatically in the EDC.  
7.1.2. Sartorius and Modified Sartorius Scores 
Twelve body areas will be evaluated at visits specified in the Time and Events Table to calculate 
the Sartorius and modified Sartorius scores: 
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 60 of 87 • left and right axillae,  
• left and right inframammary areas,  
• intermammary area,  
• left and right buttocks, 
• left and right inguino- crural folds,  
• perianal area and perineal area, and  
• other  (specify) . 
A score of [ADDRESS_788401] severe disease, and higher scores indicate increasingly severe 
disease. There is no upper limit in the score ( Sartorius et al, 2003; Sartorius et al, 2009).  
The presence of nodules, abscesses, fistulae, hypertrophic scars, and other findings will be 
recorded  in the EDC. The longest distance between two lesions and whether lesions are 
separated by [CONTACT_596816] . 
7.1.3. International Hidradenitis Suppurativa Severity Score System  
The I nternational Hidradenitis Suppurativ a Severity Score (I HS4) is simple to calculate and has 
been validated with the use of exist ing physician -derived outcomes such as HS -PGA, Hurley 
classification, MSS or Expe rt Opi[INVESTIGATOR_596784]) and patient -reported outcome measure 
(DLQI).  IHS4  score ( points) = (number of nodules multiplied by 1) + (number of abscesses 
multiplied by 2) + [number of draining tunnels (fistulae/sinuses) multiplied by 4]. A score of 3 or 
less signifies mild HS, a score of 4 –10 signifies moderate HS and a score of 11 or high er 
signifies severe HS.  
7.1.4. Hidradenitis Suppurativa -Physician Global Assessment (HS -PGA)  
The HS -PGA is an ordinal scale specific to HS that categorizes subjects into clear, minimal, 
mild, moderate, severe, or very severe disease, and it was used successfully in a phase 2 
interventional clinical trial. A recently developed six stage PGA was defined as follows ( Kimball 
et al,  2012) : 
• Clear: no inflammatory or non -inflammatory nodules  
• Minimal: Only the presence of non-inflammatory nodules 
• Mild: Less than 5 inflammatory nodules or 1 abscess or draining fistula and no inflammatory nodules 
• Moderate: Less than 5 inflammatory nodules or one abscess or draining fistula and one or more inflammatory nodules or 2–5 abscesses or draining fistulae and less than ten 
inflammato ry nodules 
• Severe: 2 –5 abscesses or draining fistulae and ten or more inflammatory nodules 
• Very severe: More than 5 abscesses or draining fistulae 
Avacopan (CCX168)   Protocol CL016_168 
[ADDRESS_788402] the maximum severity pain on a numeric rating scale from 0 (no skin pain) 
to 10 (skin pain as bad as can be imagined) in a daily diary from one week prior to Day 1 
through the Week 44 visit. 
The weekly average of the maximum severity pain for visits designated in the  Time and Events 
Table will be calculated prog rammatically.  
7.1.6. Health -Related Quality of Life Assessments  
The SF-36 v2 and EQ-5D-5L instruments are widely accepted global non -disease- specific tools 
to measure changes in subjects’ health -related quality of life. The HiSQOL index (an HS -specific 
instrument) and DLQI instruments are designed to measure the impact of HS or skin disease on 
subjects’ quality of life.  Forms for these instruments will be completed by [CONTACT_596817]. Proven translations will be used for non-English 
speaking subject s, whenever possible. 
Study site personnel will facilitate completion of the questionnaires by [CONTACT_423] s, but will not 
complete the forms for the subject s. The administrator will establish a rapport with the subject , 
emphasize the importance of completing the form, and serve to answer questions and address 
concerns. Subjects should complete the questionnaires before seeing the Investigator  at the visit. 
7.1.7. Health -Economic Information 
The WPAI:SHP (https://www.cdisc.org/foundational/qrs ) assesses the effect of general and 
specific health conditions on productivity losses. Scores are calculated for four areas: percent 
work time missed due to HS, percent impairment while wor king due to HS, percent overall work 
impairment due to HS, and percent activity impairment due to HS. Forms  for this instrument will 
be completed by [CONTACT_596818] t. 
Other health -economic i nformation  will be recorded by [CONTACT_596819][INVESTIGATOR_602] (i.e., Number of Hospi[INVESTIGATOR_596785], Number of days hospi[INVESTIGATOR_057], Number of days missed from work), Emergency or Urgent Care visit (i.e., Number of visits total and due to HS, Number of days (or hours where applicable) 
missed from work),  Lesion interventions for HS ( i.e., Number of days (or hours where 
applicable) missed from work due to HS lesion interventions). 
7.2. Safety Assessments  
7.2.1. Physical Examinations and Vital Signs  
A physical examination (including evaluation of general appearance/mental status, head, eyes, 
ears, nose, throat, and the following body systems: dermatologic, cardiovascular, respi[INVESTIGATOR_696], gastrointestinal, musculoskeletal and neurologic) will be performed at visits indicated in the  
Time and Events Table. Findings must be recorded in the source documents. 
Any new or worsening findings upon physical examination need to be recorded as adverse 
events.  
Avacopan (CCX168)   Protocol CL016_168 
[ADDRESS_788403] three minutes.  
7.2.2. Clinical Safety Laboratory Assessments 
The following tes ts will be performed at the visits identified in the Time and Events Table.  
• Hematology: At the central laboratory hemoglobin, hematocrit, RBC  count, WBC  count 
with differential, platelet c ount, mean cell hemoglobin, mean cell  hemoglobin 
concentration , mean corpuscular volume; 
• Serum Chemistry: At the central laboratory , liver panel ( total and fractionated  biliru bin, 
lactate dehydrogenase, aspartate aminotransferase [AST] , alanine aminotransferase 
[ALT] ), renal panel ( blood urea nitrogen, creatinine), creatine phosphokinase (CPK), 
albumin, sodium, potassium, magnesium, bicarbonate, chloride, calcium, inorganic 
phosphorus, glucose, total protein, alkaline phosphatase, total cholesterol, uric acid , 
serum amylase, and serum lipase; 
• Coagulation: PT and INR will be performed only if ALT and /or AST > 3x ULN;  
• Urinalysis: At the central laboratory, nitrite, blood, and protein, will be tested. If positive, 
microscopy will be per formed;  
• Virology (measured only at S creening  and may be measured  at the local laboratory): 
hepatitis B surface antigen, hepatitis C antibodies, HIV 1 and 2 antibodies; virology tests done within 6 weeks prior to S creening are acceptable for eligibility assessment ; results 
from prior virology tests performed at the local laboratory must be recorded in the EDC 
system ; 
• TB screen: Interferon γ release assay (IGRA)  through the central laboratory . 
7.2.3. Adverse Events  
An adverse event (AE) is defined as any untoward medical occurrence associated with the use of 
a drug in humans, whether or not considered drug- related. An adverse event could therefore be 
any unfavorable and/or unintended sign (including abnormal laboratory findings), symptom, or disease temporally associ ated with the use of the drug, whether or not considered related to the 
drug. This definition includes intercurrent illnesses or injuries and exacerbation of pre- existing 
conditions. 
An unexpected adverse event is an adverse event that is not identified in nature, severity, or 
frequency in the current Investigator’s Brochure, or that is of greater severity than expected 
based on the information in the Reference Safety Information listing within the Investigator’s 
Brochure.  
Avacopan (CCX168)   Protocol CL016_168 
[ADDRESS_788404] been randomized to treatment will be recorded 
in the EDC system and will be reported in accordance with regulatory requirements. Adverse 
events reported prior to commencement of administration of study drug will be considered pre-treatment events.  
All adverse events will be monitored until resolution or, if the adverse event  is determined to be 
chronic, until a cause is identified. If an adverse event remains unresolved at the conclusion of the study, a clinical assessment will be made by [CONTACT_3433] e Investigator and the Sponsor’s Medical 
Monitor to determine whether continued follow- up of the adverse event is warranted.  
[IP_ADDRESS]. Adverse Event Severity Assessment  
The severity of each adverse event will be determined by [CONTACT_596820]:  
• Mild (Grade 1): no limitation of usual activities  
• Moderate (Grade 2): some limitation of usual activities  
• Severe (Grade 3): inability to carry out usual activities  
• Life-threatening (Grade 4): an immediate risk of death  
• Death (Grade 5)  
[IP_ADDRESS]. Causality Assessment  
The relationship of study drug to an adverse event will be determined by [CONTACT_596821]: 
• Probably Not Related: the adverse event was more likely explained by [CONTACT_450539].  
• Possibly Rela ted: there is evidence for a reasonable possibility that study drug 
administration caused the adverse event . 
[IP_ADDRESS]. Adverse Events of Special Interest (A ESI) 
The following findings, as defined below, must be reported as AEs and will be considered adverse events o f interest (AE SI): 
Infections:   
For medically important infections, the organisms involved in the infection need to be determined whenever possible and  be documented in the EDC. A ll local and national vaccination 
recommendations should be followed. 
Hepatic Transaminase Elevation: 
• Grade [ADDRESS_788405]  (>5 times the upper limit of normal)   
• Grade [ADDRESS_788406]  (>3 times the upper limit of normal) with 
elevation of bilirubin to >2 times the upper limit of normal or INR >1.5 
Neutropenia, Lymphopenia, and Leuokopenia: 
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 64 of 87 • Grade 3 or greater neutropenia (<1  x 109/L) 
• Grade 4 lymphopenia  (<0.2 x 109/L) 
• Grade 3 or greater leukopenia (WBC count <2 x 109/L) 
Creatine Phosphokinase Elevation: 
• Grade 3 or greater CPK increase (>5 times th e upper limit of dosing) 
Hypersensitivity Reactions :  
• urticaria  
• angioedema  
Malignancies: 
• Any malignancies  will be reported as AEs.  
HS Lesion I ntervention s: 
• Lesion interventions as described in Section  5.7 will b e recorded as AE . 
[IP_ADDRESS]. Serious Adverse Events  
A serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose:  
• Results in death ; 
• Is life -threatening (i.e., the subject  was, in the opi[INVESTIGATOR_689], at immediate 
risk of de ath from the event as it occurred ); 
• Requires or prolongs hospi[INVESTIGATOR_059]; 
• Results in persistent or significant disability or incapacity ; 
• Is a congenital anomaly or birth defect ; 
• Is an important and significant medical event that, based on appropriate medic al 
judgment, may jeopardize the subject  and/or may require medical or surgical intervention 
to prevent one of the other outcomes defining serious. 
Elective surgery already known during Screening to occur in the course of the study, and elective 
hospi[INVESTIGATOR_596786], and agreed upon between the Investigator and the subject  prior to randomization, will 
not have to be reported as SAEs. 
[IP_ADDRESS]. SARs and S[LOCATION_003]Rs  
A serious adverse reaction (S AR) is defined as an SAE for which there is at least a reasonable 
possibility that the study drug caused the event. 
A suspected  unexpected serious adverse reaction (S[LOCATION_003]R) is defined as an SAE for which there 
is at least a reasonable possibility that the study drug caused the event, and the SAE is 
”unexpected”, i.e., not described in terms of nature, severity, or frequency in the Reference Safety Information within the current Investigator’s Brochure. 
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 65 of 87 ”Reasonable possibility” means that there is evidence to suggest a causal relationship between 
the study drug and the adverse event. Within the reporting requirements, the following examples 
illustrate the types of evidence that would suggest a causal relationship:  
• A single occurrence of an event that is uncommon and known to be strongly associated with drug exposure (e.g., angioedema, hepatic injury, Stevens-Johnson Syndrome); 
• One or more occurrences of an event that is not commonly associated with drug exposure, but is otherwise uncommon in the population exposed to the drug (e.g., tendon rupture); 
• An aggregate analysis of specific events observed in a clinical trial (such as known consequences of the underlying disease or condition under investigation or other events that commonly occur in the study population independent of drug therapy) that indicates those events occur more frequently in the drug treatment group than in a concurrent or historical control group. 
Events related to the underlying disease , such as relapses  or worsening of disease will not be 
considered as S[LOCATION_003]Rs, unless there is a reasonable possibility that avacopan  use was associated 
with the se event s. 
[IP_ADDRESS]. Laboratory Abnormalities 
Safety laboratory tests are performed frequently over the course of the study. Laboratory reports 
with abnormal findings will be reviewed by [CONTACT_737] . The Medical Monitor will review 
notably abnormal laboratory results according to the Safety Monitoring Plan. T he Investigator 
will be advised to follow subject s with notably high liver panel  tests closely and to take 
appropriate steps, such as potentially discontinuing study drug , in case the abnormalities persist.  
Please see Section  4.4 for guidance on laboratory abnormalities (white blood cell count, 
neutrophil count, lymphocyte count, AST or ALT and other lab abnormalities of impaired liver function or hepatic toxicity, CPK increase) that would prompt pausing or permanently 
discontinuing study drug. 
[IP_ADDRESS]. Pregnancies  
Any pregnancies that occur in female subject s or partners of mal e study subject s must be 
reported to the Safety team within [ADDRESS_788407] be followed up until conclusion and the outcome of the pregnancy reported 
within 24 hours of awareness to the Safety team as indicated in Section  7.2.4. 
7.2.4. Serious Adverse Event  Reporting  
Any serious adverse event occurring from Screening through the end of the follow-up period, 
whether or not considered study related, will be reported immediately (within 24 hours) to the Safety team. Reporting is done by [CONTACT_596822] . If it is not 
possible to access the EDC system, the Investigator will send an email to the clinical safety 
mailbox (see information below) of the Clinical Research Organization (CRO) or call their 
regional SAE hotline and fax the completed SAE report form within [ADDRESS_788408] details are as follows:  
A vac o pa n ( C C X 1 6 8)   Pr ot oc ol C L 0 1 6 _ 1 6 8 
3 1 J ul y 2 0 1 9  A me n d me nt 2. 0 
C he m o Ce ntr y x, I n c.  C O N FI D E N TI A L  Pa ge 6 6  of 8 7  C R O Cli nical Safet y  e-m ail :    
C R O S A E h otli ne:  
C R O Facsi mile:   
A n y me di cati o n or ot her t hera pe utic meas ures us e d t o treat t he e ve nt, i n a d diti o n t o t he o utc o me 
of t he a d verse e v e nt , will be rec or de d i n t he E D C s yste m. 
F oll o w- U p Re p orts: 
T he I n vesti gat or m ust c o nti n ue t o f oll o w t he s u bject u ntil t he S A E has s u bsi de d or u ntil t he 
c o n diti o n bec o mes c hr o nic i n nat ure, sta bilizes (i n t he case of persiste nt i m pair me nt) , or t he 
s u bject dies.  
Wit hi n [ADDRESS_788409] u d y a n d s u b mit a n y s u p p orti n g d oc u me ntati o n (e. g., 
s u bject disc har ge s u m mar y or a ut o ps y re p orts) t o t he C R O Cli nical Safet y t ea m via fa x  or e -mail. If it is n ot p ossi ble t o access t he E D C s yste m, refer t o t he pr oce d ures o utli ne d a b o ve f or i nitial re p orti n g of S A Es. 
T he S p o ns or or its re pr ese ntati ves will re p ort all S U S A Rs t o nati o nal healt h a ut h orities a n d 
ce ntral et hics c o m mittees i n a n e x pe dite d ma n ner i n acc or d a nce wit h Cli nical Trial Directi ve, 
Articles 1 6 a n d 1 7, I C H G ui deli ne E 2 A a n d E N T R C T 3 o n t he re p orti n g of all S U S A Rs. 
I n v esti gat ors will f or war d a n y s afet y c o m m u nicati o n as a p plica ble t o t heir local et hics c o m mittees.  
7. 3.  P h ar m ac o ki ne tic Assess me nts 
C o nce ntrati o ns of a v ac o p a n  (a n d meta b olites) will be deter mi ne d i n plas ma acc or di n g t o t he sc he d ule i n t he Ti me a n d E ve nts Ta ble . The d ate a n d ti me of t he last d ose of st u d y dr u g pri or t o t he sa m ple c ollecti o ns m ust be rec or d e d i n t he E D C s yste m . T he dat e a n d ti me of t he P K sa m ple c ollecti o n m ust als o be rec or de d. 
T otal plas ma c o nce ntrati o ns of a vac o p a n  ( a n d meta b olites) will be deter mi ne d usi n g v ali date d 
a nal yti cal met h o ds.  
7. 4.  E x pl or at or y Bi o m ar ker Assess me nts  
S u bjects  w h o c o nse nte d will ha ve t heir plas ma c ollecte d f or bi o mar k er ass ess me nts i ncl u di n g f or 
e x a m ple c o m ple me nt fra g me nts i nfla m mat or y c he m o ki ne a n d c yt o ki nes.  T he c ollecti o n will 
occ ur acc or di n g t o t he s c he d ule i n t he  Ti me a n d E ve nts Ta ble. 
7. 5.  P h ot o gr a p h ic Assess me nts 
P h ot o gra p hs of aff ecte d s ki n a n d lesi o ns will be ta ke n t o d oc u me nt t he c h a n ges i n vis ual a p pear a nce a n d se v erit y o ver t he c o urse of st u d y treat me nt  i n s u bjects w h o c o nse nte d . 
I n v esti gat ors will use t hese p h ot o gr a p hs t o c o m pare t heir c urre nt a n d pri or lesi o n assess me nts. I n 
rare cases, t h e I n vesti gat or ma y us e a n a n o n y mize d p h ot o gr a p h t o c o ns ult wit h t he st u d y tea m t o ass ure acc ur ac y a n d c o nsiste nc y of t he assess me nts.  P P D
P P D
P P D
Avacopan (CCX168)   Protocol CL016_168 
[ADDRESS_788410] ’s condition will b e evaluated by [CONTACT_596823] e clinical trial and subjects will be returned to  standard  of care 
medical treatment , at the Investigator’s discretion . For early withdrawals from the study, the 
procedures for the Early Termination visit will be performed , when possible (see Section  6.14) . 
8. STATISTICAL CONSIDERATIONS 
8.1. Timing of Analyses  
Primary Analysis:  This study consists of a 12- week placebo -controlled, double- blind treatment 
period (Period 1), followed by a 24- week active treatment period  (Peri od 2). When the last 
subject  has completed or dropped out of Period 1, an unblinded analysis of the data collected 
from Period [ADDRESS_788411] , study site  
personnel at the site, or the Sponsor until the end of the study. 
Final Analysis : When all  subject s have completed all of the Week [ADDRESS_788412] s achieving a Hidradenitis Suppurativa 
Clinical Response (HiSCR) after [ADDRESS_788413] has 
completed Period 1: 
• The null hypothesis (H 0) is that the avacopan group is not different from the placebo 
control group when comparing the HiSCR rate at Week 12. 
• The alternative hypothesi s (H 1) is that the avacopan group is different from  the placebo 
control group when comparing the HiSCR rate at Week 12. 
To address the multiplicity issue with two dose groups, a fixed hierarchical testing sequence will 
be employed. The hypothesis testing will test the avacopan [ADDRESS_788414] is significant at the α = 0.05 level, the avacopan 10 mg vs. placebo will be tested at the α = 0.[ADDRESS_788415] of avacopan 30 mg vs. placebo is not significant at the α = 0.05 level, the 
avacopan 10 mg vs. placebo will be tested as an exploratory analysis . 
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 68 of 87 8.3. Sample Size Determination  
The study will enroll approximately 390 subjects. In two Phase 3 clinical trials with adalimumab 
(PI[INVESTIGATOR_15597] I and II ; Kimball et al, 2016 a), the proportions of subjects in the placebo control 
group achieving a HiSCR at Week 12 were 26.0% and 27.6%, respectively. Hence, if the control 
group only receives placebo, one may assume a HiSCR at Week 12 of approximately 30%. The 
average HiSCR at Week 12 in the adalimumab groups in PI[INVESTIGATOR_15597] I a nd II were 41.8% and 
58.9%, respectively with an average of approximately 50% (Kimball et al, 2016a ). The attrition 
rate through out the trial is estimated to be approximately 7%. A sample size of approximately 
130 subjects per treatment g roup (390 in total) at a Type I error rate of α = 0.05 (two -sided) 
provides approximately 90% power to detect a 20% superiority of avacopan compared to the placebo control group in HiSCR at Week 12, assuming an HiSCR at Week 12 of 50% in the avacopan group.  
8.4. Analysis Populations  
8.4.1. Mod ified Intent -to-Treat Population 
For the purposes of efficacy data analysis, the Modified Intent- to-Treat ( mITT) population will 
be used. This population will include all subject s who are randomized and received at least one 
dose of study drug . The efficac y population will be analyzed according to the treatment grou p 
each subject is randomized to. The mITT population will be the primary analysis population for 
the efficacy analysis.  
The mITT populations are defined for the two treatment periods as the follo wing:  
• The mITT1 Population in Period [ADDRESS_788416] one dose of study drug during Period 1. 
• The mITT2 Population in Period [ADDRESS_788417] one d ose of study drug during Period 2. 
8.4.2. Per-Protocol Population  
The Per-Protocol (PP) population will consist of all randomized subject s who receive at least one 
dose of study drug and do not have protocol deviations that could significantly affect the 
interp retation of the results for the primary endpoints. Subject s’ inclusion/exclusion from the PP 
population will be determined and documented prior to the database lock and unblinding. 
8.4.3. Safety Population 
The Safety Populations are defined as the following:  
• The S afety Population in Period [ADDRESS_788418] one dose of study drug during Period 1. 
• The Safety Population in Period [ADDRESS_788419] one 
dose of avacopan d uring Period 2. 
• The All Avacopan Treated Population is defined as all subjects who receive at least 
one dose of avacopan in any treatment period . 
Avacopan (CCX168)   Protocol CL016_168 
[ADDRESS_788420] will be included in the analysis group of the treatment actual ly received.  
8.5. Efficacy Endpoints  
8.5.1. Primary Endpoint  
The primary endpoint is the proportion of subjects achieving Hidradenitis Suppurativa Clinical 
Response (HiSCR) at Week 12. 
This endpoint is considered appropriate because it was able to measure meaningful 
improvements in HS subjects in previous studies ( Kimball et al, 2014; Zouboulis et al, 2015; 
Kimball et al, 2016b) . This  endpoint was also used successfully in two Phase 3 clinical trials 
with adalimumab ( Kimball et al, 2016a ). 
8.5.2. Secondary Efficacy Endpoints  
Secondary efficacy endpoints include: 
1. Reduction of IHS4 score relative to baseline at Week 12; 
2. Proportion of subjects achieving at least 30% reduction and at least [ADDRESS_788421]’s global assessment of skin pain (NRS30) in subjects with a baseline 
NRS of at least 3, evaluated at Week 12; weekly averages of daily pain will be calculated 
based on subjects’ daily diary recording of the worst pain experienced in the previous 24 hours; 
3. Change from Day 1 to Week 12 in the modified Sartorius score to quantify the severity change of HS;  
4. Proportion of subjects with baseline Hurley Stage II who achieved an abscess and inflammatory nodule count of 0, 1, or 2 at Week 12. 
8.5.3. Other Efficacy Endpoints  
The following efficacy endpoints  will be analyzed from Day 1 to each timepoint up to Week 44, 
where applicable: 
1. Proportion of subjects achieving HiSCR ; 
2. Proportion of subjects achieving at least 30% reduction and at least [ADDRESS_788422]’s global assessment of skin pain (NRS30), in subjects with a Day [ADDRESS_788423] 3;  
3. Proportion of subjects with baseline Hurley Stage II who achieved an abscess and inflammatory nodule count of 0, 1, or 2; 
4. Change from Day 1 in inflammatory nodule count, abscess count, draining fistula count, and 
total AN count; 
5. Change from Day 1 in the Sartorius score, modified Sartorius score, IHS4 score , and HS-
PGA to quantify the severity change of HS; 
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 70 of 87 6. Change from Day 1 in patient-reported outcomes: SF -36 v2, EQ-5D-5L, HiSQOL, and  
DLQI ; 
7. Proportion of subjects who experienced flare, defined as an at least 25% increase in AN 
counts with a minimum increa se of 2 AN lesions relative to Day 1 ; 
8. Duration of flare in days (calculated from the day when flare is observed to the day prior to the observation that flare is no long er present; of  note, there could be multiple periods that 
flares are observed, in which case, the total days from the  multiple periods will be used); 
9. Proportion of subjects who experience at least 25% increase in draining fistula counts with a minimum increase of 2  draining fistula counts relative to Day 1 ; 
10. During Period 2, Proportion of subjects with a loss of response (LOR) , defined as loss of at 
least 50% of AN count improvement achieved from Day 1  to Week 12; 
11. Time to LOR  during Period 2; 
12. Proportion of subjects who received oral antibiotic rescue therap y; 
13. Proportion of subjects who start disallowed opi[INVESTIGATOR_416266]; 
14. Proportion of subjects who undergo lesion intervention due to HS; 
15. Number of lesion interventions due to HS; 
16. Health -economic information: 
a. WPAI:SHP:  Change from Day 1  to each timepoint during Period 1 and Change from 
Week 12  to each timepoint  during Period 2 and including the follow-up period; 
b. Hospi[INVESTIGATOR_602] (cumulative): Number of Hospi[INVESTIGATOR_596785], Number 
of days hospi[INVESTIGATOR_057], Number of days missed from work; 
c. Emergency or Urgent Care visit s (cumulative): Number of visits total and due to HS, 
Number of days (or hours where applicable) missed from work; 
d. Lesion interventions for HS (cumulative): Number of days (or hours where applicable) missed from work due to HS lesion interventions. 
8.6. Safety Endpoints  
Safety  endpoints include: 
1. Subject incidence of treatment -emergent serious adverse events, adverse events, and 
withdrawals due to adverse events;  
2. Change from D ay 1 and shifts from D ay 1 in all safety laboratory parameters;  
3. Change from D ay 1 in vital signs and significant changes in physical examination 
abnormalities.  
8.7. Pharmacokinetic Endpoints  
Avacopan (and its  metabolite) plasma concentration s will be used to calculate the following PK 
parameters on Day 1 and trough plasma concentrations (C min) over th e course of the clinical trial.  
Cmax Maximum plasma concentration  
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 71 of 87 Tmax Time of maximum plasma concentration  
AUC 0-6h Area under the plasma concentration -time curve from Time 0 to Hour 6 on Day 1 
8.8. Statistical Analysis Methodology  
8.8.1. General Approach  
All study data will be summarized by [CONTACT_53846]. Categorical variables 
will be reported as frequency and percent (e.g., gender, race). Continuous variables will be 
reported as number of subjects, mean, standard deviation, median, minimum, and maximum (e.g., age, weight). All summaries, statistical analyses, and individual subject data  listings  
described below will be completed using Version 9.3 or later of the SAS Statistical Analysis System (SAS Institute, Inc. Cary, NC).  
All statistical testing will be two -sided, with the T ype I error rate at α = 0.05.  
Baseline is defined as the last value prior to start of dosing with study drug (typi[INVESTIGATOR_596787] 1 
pre-dose value).  
Non-Responder Analysis:  For non-responder analysis, t he following imputation rules  will be 
applied to catego rical and continuous efficacy variables, respectively: 
• Categorical Efficacy Variables: Non-Responder Imputation (NRI) will be used as the 
primary analysis . Last Observation Carried Forward (LOCF) will be the secondary 
approach for the non-responder analysi s. 
• Continuous Efficacy Variables: LOCF will be used as the primary analysis.  The valid 
asses sments from last visit prior to the visit the subject was considered a non -
responder will  be carried forward to the end of study for continuous efficacy 
variables. Baseline efficacy evaluations will not be carried forward.  
The following are examples for subjects who will be counted as non-responder:  
• Concomitant anti- TNF -α treatment  or other treatments with clinically relevant impact 
on HS; 
• Antibiotic rescue therapy ; 
• Non-protocol specified lesion inter vention, or higher than permitted frequency or 
number of pre -specified lesion interventions. Protocol-specified lesion interventions 
will not be counted as Non-responder. 
Concomitant therapy that would qualify a subject as no n-responder will be reviewed prior to 
database lock. More details will be provided in the Statistical Analysis Plan  (SAP) . 
Missing Data Analysis:  For missing data  analysis, the following imputation rules will be applied 
to categorical and continuous efficacy variables, respectively : 
• Categorical Efficacy Variables: NRI will be the primary approach for categorical 
variables. The NRI analysis will count subjects who have missing values at a specific 
visit as  non-responders for that visit. LOCF will be th e secondary approach for the 
missing data  analysis.  
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 72 of 87 • Continuous Efficacy Variables: LOCF  will be the primary approach for continuous 
efficacy variables  of missing data . The LOCF analyses will have their valid efficacy 
assessments from the previous visits to  impute missing data at later visits. Baseline 
efficacy evaluatio ns will not be carried forward. 
Lesions that received intervention (incision and drainage, or intralesional injection) will be 
counted as permanently present from the date of the intervention. 
Details of the statistical analysis will be provided in a separate statistical analysis plan (SAP), 
which will be finalized  prior to database lock . 
8.8.2. Analysis of Primary Efficacy Endpoint 
The primary efficacy en dpoint, the proportion of subjec ts achieving  HiSCR at Week 12 will be 
tested using the Cochran -Mantel -Haenszel (CMH) test, stratified by [CONTACT_596824]  (Stage II vs . 
III), c oncomitant  antibiotic therapy with allowed antibiotics (Yes vs . No)  and anti -TNF drug use  
(Treatment naïve vs . Previous treatmen t). The hierarchical testing procedure will be used for t he 
comparisons of the [ADDRESS_788424]: if the p -value is 
less than or equal to 0.05, then 10 mg avacopan vs. placebo will be tested at the α = 0.[ADDRESS_788425] of avacopan 30 mg vs. placebo is not significant at the α = 0.05 level, the 10 mg avacopan vs. placebo will be tested as an exploratory analysis. Th e two -sided 95% confidence 
intervals for the difference in proportions (avacopan minus placebo control) will be calculated using the stratified Newcombe hybrid -score method . The primary efficacy analysis will be 
carried out in the mITT1 Population. In addition, the primary efficacy endpoint will be analyzed in the Per -Protocol Population. 
The proportion of subjec ts achieving HiSCR at Week [ADDRESS_788426] a 50% reduction from baseline in abscess and inflammatory nodule count, with no 
increase in abscess count and no increase in draining fistula count number at Week [ADDRESS_788427] 
stratified for baseline Hurley Stage (Stage II vs. III), concomitant antibiotic therapy with allowed antibiotics (Yes vs. No) and anti- TNF -α drug use (Treatment naïve vs. Previous treatment) 
similar to the analysis of  the primary efficacy endpoint. 
Continuous variables will be analyzed using a mixed effects model for repeated measures. This model will include  treatment group, visit, treatment- by-visit interaction, and randomization strata 
(Hurley Stage II or Hurley Stage III, previous anti -TNF -α drug use or anti- TNF -α drug naïve, 
concomitant antibiotic therapy use or not ) as factors, and baseline as covariate. Subject s will be 
considered as repeated measure units over visits. Testing p -values, p oint estimates and 
corresponding 95% confidence intervals will be estimated for the difference between the 
Avacopan (CCX168)   Protocol CL016_168 
[ADDRESS_788428]’s global assessment of skin pain (NRS30) up to Week 12, subjects 
who rec eived analgesics of disallowed  pain  therapy will be counted as non- responder for 
categorical variables . For continuous variables, LOCF applies. Hereby, the last pain assessment 
is carried forward from the start day of the analgesics or day of the intervention until [ADDRESS_788429] of 1 0 mg vs. 30 mg avacopan groups will be conducted at each timepoint for the 
endpoint of the proportion of subjects achieving HiSCR and the secondary endpoints. A detailed 
Type I management plan for the secondary endpoint testing will be provided in SAP. 
8.8.4. Analy sis of S econdary and Other Efficacy Endpoints  in Period 2  
The efficacy data for secondary and other endpoints by [CONTACT_596825] 2 will be summarized 
using the mITT 2 population.  Analysis of other efficacy endpoint s will be conducted from Day 1 
to each timepoi nt. 
For the analysis of time to loss of response (LOR), the treatment difference between the [ADDRESS_788430] . 
All reported adverse events will be coded using MedDRA and listed by [CONTACT_1196], 
Preferred Term, and verbatim term.  
• Treatment -emergent adverse events will be summarized and listed by [CONTACT_596826], by [CONTACT_596827].  
• Treatment -emergent serious adverse events and adverse events leading to withdrawal will 
be summarized by [CONTACT_1570].  
Individual vital signs and change from baseline in vital signs will be summarized by [CONTACT_596828], subject, and study visit. 
Laboratory data will be listed by [CONTACT_1570], subject , and study visit. Abnormal laboratory 
values will be flagged. Laboratory data (actual values and change from baseline) will be 
summarized by [CONTACT_67486]. Shift tables will be generated for shifts in 
laboratory parameters by [CONTACT_15449].  
Avacopan (CCX168)   Protocol CL016_168 
[ADDRESS_788431] subset 
only. The following parameters will be determined, where possible: 
Cmax Maximum plasma concentration  
Tmax Time of maximum plasma concentration  
AUC 0-3h Area under the plasma concentration -time curve from Time [ADDRESS_788432]- Day 1 visits  
The relationship between PK parameters (e.g., C min) and efficacy endpoints such as HiSCR may 
also be evaluated.  
8.8.7. Subject  Disposition  
The number of subject s who were screened, who screen failed (by [CONTACT_48933]), who were 
randomized, who completed Week 12, Week 36, and Week [ADDRESS_788433]  baseline characteristics and demographic data, i.e., age, sex, race, ethnicity, weight, 
height, body mass index, anatomic location of HS, number of inflammatory nodules, absce sses, 
draining fistulae and hypertrophic scars, Hurley Stage of HS, HS disease duration (from time of 
diagnosis), subject’s global assessment of skin pain NRS, Sartorius and modified Sartorius scores, IHS4 score, and HS -PGA, previous systemic treatment, pr evious antibiotic treatment, 
previous TNF inhibitor use, prior surgery for HS, SF-36 v2, EQ-5D- 5L, and HiSQOL i ndex will 
be summarized and listed by [CONTACT_1570]. 
Physical examination abnormalities, medical history, previous and concomitant medications (including HS medication use) at study entry will be summarized and listed by [CONTACT_1570] . 
8.8.9. Prior and Concomitant Medications  
All medications will be coded using the World Health Organization Drug Dictionary (WHODD) . 
All prior (within 12 months of S creening for HS medications, and within 6 months of S creening  
for all other medications ) and concomitant medications (including HS  medication s) will be 
summarized and listed by [CONTACT_596829] (ATC)  classification  and 
preferred term . 
8.8.10. Study  Drug Exposure and Compliance  
Subject  drug exposure will be calculated comparing  the daily drug diary, study drug dispensing 
and return records , as well as avacopan  plasma concentrations over the course of the study . The 
study drug exposure (duration, total dose, and average daily dose) and compliance will be 
summarized for the double-blind and active treatment periods separately. Individual subjec t data 
listing s will also be provided. 
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 75 of 87 8.8.11. Handling of Missing Data 
For binary variables, non-response imputation will be used for missing data (primary approach). 
Sensitivity analyses will include last observation carried forward (LOCF) and multiple 
imputation. For continuous variables, LOCF and observed without adjustment for missing data will be performed as sensitivity analyses. Baseline data will not be carried forward.  
8.8.12. Covariates and Subgroups  
The analysis of the efficacy endpoints may be adjusted by [CONTACT_596830] , stratified analysis , and/or subgroup analysis: 
• Randomiza tion stratification variables  
− Hurley Stage II vs. Hurley Stage III  
− Concomitant  antibiotic therapy (Yes vs. No)  
− Anti-TNF -α treatment (Treatment naïve vs. P revious treatment)  
• Sex 
• BMI  
• Baseline weight  
• Age at diagnosis of HS  
• Age at study  entry  
• Duration of HS  
• Subject ’s age , race,  and ethnicity  
• Baseline inflammatory nodule count 
• Baseline abscess count  
• Baseline draining fistula count  
• Baseline Sartorius and modified Sartorius scores 
• Baseline AN count  
• Geographic distribution  
8.9. Interim Analyse s 
An interim analysis for futility may be conducted (for example, if enrollment is much slower than expected) by [CONTACT_596831]  30% of the planned study 
participants have completed Period [ADDRESS_788434] completed the full study. 
Avacopan (CCX168)   Protocol CL016_168 
[ADDRESS_788435]  has completed the study when s/he has completed the study procedures per protocol. 
9.2. Study Termination  
The end of study is defined as t he last study visit of the last clinical trial subject . 
The study will be terminated early if there is an insurmountable safety concern  that cannot be 
addressed by [CONTACT_12548]. This will be determined in conjunction with the DMC. In this 
case, the I nvestigators, competent authorities ( CAs), IRB/ECs will be notified expeditiously and 
appropriate measures taken to safeguard the study subjects.  
10. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS  
10.1. Regulatory, Ethical, and Study Oversight Consideration s 
10.1.1. Informed Consent  
A properly executed, written, and appropriately explained Informed Consent Form, in 
compliance with the Declaration of Helsinki, ICH GCP, and US Code of Federal Regulations for Protection of Human Subjects (21 CFR 50.25[a,b], CFR 50.27, and CFR Part 46, Subpart A), 
will be signed by [CONTACT_596832]. Consent forms will be provided to 
subjects in their native language and will describe in detail the study intervention, study 
procedures, and risks. 
Informed consent i s a process that is initiated prior to the individual’s agreeing to participate in 
the study and continues throughout the individual’s study participation. Consent forms will be 
approved by [CONTACT_596833]. The I nvestigator or the Investigator’s designee will explain the clinical trial to the 
participant and answer any questions that may arise. A verbal explanation will be provided in terms suited to the participant’s comprehension of the purposes, procedures, and potential risks 
of the study and of their rights as research participants. Participants will have the opportunity to 
carefully review the written consent form and ask questions prior to signing. The participants should have the opportunity to discuss the study with their family or surrogates or think about it 
prior to agreeing to participate. The participant will sign the informed consent document prior to 
any procedures being done specifically for the study. Participants mus t be informed that 
participation is voluntary and that they may withdraw from the study at any time, without 
prejudice. The rights and welfare of the participants will be protected by [CONTACT_596834] a dversely affected if they decline to participate 
in this study.  A copy of the informed consent document will be given to the participants for their 
records. The informed consent process will be documented in the source document (including the date), and the form signed, before the participant undergoes any study -specific procedures.  
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 77 of 87 10.1.2. Study Discontinuation and Closure  
Determination of unexpected, significant, or unacceptable risk to participants may warrant 
termination or suspension of the clinical trial. Wri tten notification, documenting the reason for 
study suspension or termination, will be provided by [CONTACT_596835]/competent authorities . If the study is prematurely terminated 
or suspended, t he Principal Investigator [INVESTIGATOR_596788]/EC, and will provide the reason(s) for the termination or suspension. Study 
participants will be contact[INVESTIGATOR_530], as applicable, and be informed of changes to study visit schedule. 
The s tudy may resume once concerns about safety, protocol compliance, and data quality are 
addressed, and satisfy the applicable IRBs/ECs and  regulatory agencies/competent authorities . 
10.1.3. Confidentiality and Privacy 
Participant confidentiality and privacy is strictly held in trust by [CONTACT_3486], 
their staff, and the Sponsor and its designees . This confidentiality is extended to cover testing of 
biological samples in addition to the clinical information relating to participants. The refore, the 
study protocol, documentation, data, and all other information generated will be held in strict confidence. No information concerning the study or the data will be released to any unauthorized 
third party without prior written approval of the Sponsor. 
All research activities will be conducted in as private a setting as possible.  
The study monitor, other authorized representatives of the Sponsor, representatives of the 
IRB/EC, regulatory agencies/competent authorities may inspect all documents an d records 
required to be maintained by [CONTACT_737], including but not limited to, medical records 
(office, clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the participants in this study. The clinical study site s will permit access to such records.  
The s tudy participant’s contact [CONTACT_65246]. At the end of the study, all records will continue to be kept in a secure location for as long a period as dictated by [CONTACT_3488] /EC, Institutional policies, 
or Sponsor requirements. 
Study participant research data, which is for purposes of statistical analysis and scientific reporting, will be transmitted  to and stored at the Sponsor’s designated CRO . This will not 
include the participant’s contact [CONTACT_1290]. Rather, individual participants and 
their research data will be identified by a unique study identification number. The study data 
entry and study management systems used by [CONTACT_596836]’s staff will be 
secured and password protected. At the end of the study, all study databases will be de- identifie d 
and archived at the Sponsor’s designated CRO. 
10.1.4. Future Use of Stored Specimens and Data  
Data collected for this study will be analyzed and stored at the Sponsor’s designated CRO. At the 
end of the study, these data will be transferred to the Sponsor or to a Sponsor-delegated storage 
location . 
Biological samples collected from study participants will be shipped from the study sites to the 
CRO’s central laboratory for analysis. Plasma samples collected for PK analysis will be shipped 
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 78 of 87 from the CRO’s central laboratory to the Sponsor’s designated PK laboratory for analysis. Once 
the assays are completed, the data verified, and all analyses completed, the samples will be 
destroyed. 
10.1.5. Key Roles and Study Governance 
[IP_ADDRESS]. Investigator Responsibilities  
The Investigator and site  staff will be the primary contact [CONTACT_596837]. The Investigator 
and its staff will communicate all relevant study -related information  to the subjects and conduct 
all study -specific procedures including collection of blood and urine samples. The Investigator 
agrees that neither s/he nor any of the study staff will supply study drug to any persons other than 
those enrolled in the study. 
Prior to trial initiation, the Investigator will provide the Sponsor with a fully executed and signed 
FDA Form 1572, a Financial Disclosure Form, and a curriculum vitae. Financial Disclosure 
Forms will also be completed for all sub-Investigators listed on the Form 1572 who will be 
involved directly in the treatment or evaluation of research subjects in this trial.  
The study will be conducted in accordance with the Declaration of Helsinki (amended by [CONTACT_941] 59th 
World Medical Association General Assembly, October 2008) and GCP  according to ICH 
guidelines. Specifically, the study is based on adequately performed laboratory and animal 
experimentation; the study will be conducted under a protocol reviewed by a properly constituted 
IRB/EC; the study will be conducted  by [CONTACT_63043]; the 
benefits of the study are in proportion to the risks; the rights and welfare of the subjects will be 
respected; and each subject or his/her legal guardian will give his/her written Informed Consent before any protocol- specific tests or evaluations are performed.  
The Investigator agrees to complete a subject identification register, which will be used for the purpose of long term follow-up, if needed. This form will be treated as confidential, and will be 
filed by [CONTACT_37888] a secure locked place. Otherwise, all reports and communications 
relating to the study will identify participants by [CONTACT_396949]/or assigned number only.  
[IP_ADDRESS]. Sponsor and Its Designees  
This clinical trial will be sponsored by [CONTACT_596792], Inc. ChemoCentryx will designate to its 
CRO several clinical trial activities including those related to study oversight, clinical, medical 
and safety monitoring, site communication, data management, safety laboratory measurements, statistical analysis, report writing, and site contract and investigator payment. The Sponsor will 
maintain oversight by [CONTACT_596838]. The Sponsor will also 
designate measurement of plasma PK samples to a CRO that will use validated  methods for 
measurements of avacopan and metabolites.  
[IP_ADDRESS]. Institutional Review Boards/Ethics Committees  
Prior to initiating the study, the Investigator will obtain written confirmation from the IRB/EC that the IRB/EC was properly constituted and met the definition of all [LOCATION_002] Code of Federal Regulations Title 21, Section 312.3(b) and Part 56, and/or the applicable local, regional 
or national Regulatory requirements. A copy of the confirmation will be provided to the Sponsor. 
The Principal Investigator  [INVESTIGATOR_298293]/EC with all appropriate materials, including the 
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 79 of 87 protocol and Informed Consent documents. The trial will not be initiated until IRB/EC approval 
of the protocol, the Informed Consent document, and all recruiting materials are obtained in 
writing by [CONTACT_187641][INVESTIGATOR_596789]. Appropriate reports on the progress of the study will be made to the IRB/EC and the Sponsor by [CONTACT_079] 
[INVESTIGATOR_596790] a greement with the policy 
established by [CONTACT_1034]. 
10.1.6. Safety Oversight and Data Monitoring Committee 
The study Medical Monitor will review aggregate blinded safety data regularly over the course 
of the study according to the Safety Monitoring Plan. The Medi cal Monitor will keep the 
Sponsor’s Medical Director apprised of all relevant safety findings over the course of the study. 
In addition to continuous safety monitoring by [CONTACT_596839], an external 
Data Monitoring Committee (DMC) w ill monitor the safety of subjects over the course of the 
study. The DMC will consist of external physicians and a biostatistician,  with at least one 
member being a dermatologist knowledgeable in HS. Members of the DMC will be independent from the study conduct and free of conflict of interest. A DMC charter will be developed and the 
DMC will function according to the charter. 
It is anticipated that the DMC will have regular meetings  as specified by [CONTACT_596840]. Ad hoc meetings may be scheduled if unanticipated safety 
events occur. After review of data at each meeting, the DMC will make recommendations about further conduct of the study. 
Safety data from the study will be summarized for review by [CONTACT_596841] r the 
course of the study. 
No Type I error adjustment will be made based on the DMC review of the data, since results 
from these analyses will be kept confidential and not be shared with the study team, 
Investigators, or subjects. 
10.1.7. Study Monitoring  
The Sponsor has ultimate responsibility to take all reasonable steps to ensure proper conduct of 
the study with respect to subject rights and safety, adherence to the currently approved 
protocol/amendment, compliance with ICH GCP and applicable regulatory requirements, and 
data validity and integrity.  
Study monitoring responsibility may be transferred to a Sponsor representative or CRO, who will 
be held to execute the study with high standards. 
The study will be closely monitored throughout its duration, in the form of personal visits with 
the study investigator/ site staff as well as appropriate communications by [CONTACT_756], fax, mail, or 
email. The purpose of these contacts is to review study progress, Investigator and subjec t 
adherence to the protocol, to ide ntify and mitigate any risk of subject safety , and to evaluate data 
integrity.  
The following key areas will be assessed as part of study site monitoring on an ongoing basis , in 
addition to the details provided in the Clinical Monitoring Plan: 
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 80 of 87 • Continued suitability and qualification of the site to conduct the study, including proper 
training of the Investigator and site staff ; 
• Informed consent and other regulatory documentation; 
• Subject accrual and follow up ; 
• Continued compliance with protocol, including documentation of protocol deviations and implementation of corrective and preventive measures; 
• Documentation of all adverse events and concomitant medications, and proper reporting 
of all serious adverse events;  
• Timely data entry, a ccuracy, completeness and 1 00 % verifiability of data when 
compared to source documents, and 
• Study drug accountability . 
The Investigator and their staff are expected to cooperate and support monitors during their visits 
and provide access to relevant study documents and systems. A monitoring report and visit 
follow up communication will be generated for every visit and filed in the trial master files.  
10.1.8. Quality Assurance and Quality Control 
Clinical site s are responsible for quality management of the study and proper documentation. 
Quality control (QC) procedures to ensure data quality will be accomplished through 
implementation of a validated data entry system and data QC checks that will be run on the study 
database. As part of monitoring, a ny missing data or data anomalies will be communicated to the 
site(s) for clarification/resolution.  
Following written SOPs , the monitors will verify that the clinical trial is conducted , data are 
generated and biological specimens are collected, documented (recorded), and reported in compliance with  the protocol, ICH GCP , and applicable regulatory requirements (e.g., Good 
Laboratory Practices, Good Manufacturing Practices).  
All study site documentation pertaining to this clinical study may be subject to quality assurance audits by [CONTACT_596842], the FDA, and/or other regulatory agencies with similar responsibilities.  Upon request, the auditor will have access to inspect, copy, review 
and audit all source documentation and eCRFs. Other documentation subject to quality assurance audits include the Investigator’s IRB files, study staff training and delegation records, laboratory 
certifications, pharmacy processes and standard operating procedures for study management 
processes. In addition, the S ponsor or designee may inspect conditions of storage of study drug, 
and observe any aspect of the clinical study or its supporting activities both from within and 
outside of the Investigative site. 
10.1.9. Data Handling and Record Keepi[INVESTIGATOR_007]  
[IP_ADDRESS]. Data Collection and Management Responsibilities 
Data collection is the responsibility of the clinical trial staff at the site under the supervision of 
the Investigator. The Investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness of the data reported.  
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 81 of 87 All source documents should be completed in a neat, legible manner to ensure accurate 
interpretation of data. 
Data recorded in the electronic data capture (EDC) system must be consistent with the data 
recorded on the source documents. 
Clinical data (including  disease characteristics , medical history, subject-reported outcome 
measures , AEs , and concomitant medications) will be entered into the CRO’s database, a [ADDRESS_788436] protection and 
internal quality checks, such as automatic range checks, to identify data that appear inconsistent, 
incomplete, or inaccurate. Clinical data will be entered directly from the source documents.  
Central laboratory data will be captured  and transferred  directly from the laboratory database.  
Upon completion of the study, electronic copi[INVESTIGATOR_596791]/her study files and retained as per FDA or local regulations. 
[IP_ADDRESS]. Study Records Retention  
Study documents should be retained for a minimum of [ADDRESS_788437] be developed by [CONTACT_3483]. 
It is the responsibility of the Investigator to use continuous vigilance to identify and report 
significant protocol deviations to the Clinical Research Associate (CRA)  as soon as possible 
upon identification of the protocol deviation. All deviations must be addressed in study source 
documents. Protocol deviations must be sent to the IRB/EC per their policies. The Investigat or is 
responsible for knowing and adhering to the reviewing IRB /EC requirements. 
Significant protocol deviations will be listed and summarized by [CONTACT_596843]. 
The Sponsor will assess any protocol deviations and decide whether any of these should be 
reported to CAs  as a serious breach of GCP and the protocol. Protocol waivers are not 
acceptable.  
10.1.11. Protocol Modifications 
Only the Sponsor may modify the protocol. The only exception is when the Investigator considers that a subject’s safety would be compromised without immediate action. In this 
circumstance, immediate approval of the chairperson of the IRB/EC must be sought, and the 
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 82 of 87 Investigator should inform the Sponsor’s Medical Monitor and the full IRB/EC within five 
working days after the emergency occurred.  
All other amendments that have an impact on subject risk or the study objectives, and/or that require revision of the ICF, must receive approval from the IRB/EC prior to their 
implementation, except when the changes invol ve only logistical or administrative aspects of the 
trial. The IRB/EC must be notified of changes that are made to study contact [CONTACT_6404], but 
IRB/EC review or approval of these changes is not required. If protocol amendments are 
substantial and are likely to have an impact on the safety of the trial subjects or to change the 
interpretation of the scientific documents in support of the conduct of the trial, or if they are otherwise significant, the Sponsor shall notify the FDA and other CAs concerned of th e reasons 
for, and content of, these amendments according to the European Directive “Detailed guidance on the request to the CAs for authorization of a clinical trial on a medical products for human use, the notification of substantial amendments and the declaration of the end of trial (CT 
1)(2010/C 82/01)” and other regulatory guidance. In case of a substantial amendment to the 
protocol, approval will be sought from CAs before implementation. 
10.1.12. Study Registration, Use of Information and Publication 
The study will be registered in clinicaltrials.gov and other country -specific registries, as required, 
prior to initiation.  
It is understood by [CONTACT_596844]. To allow for the use of information derived from the 
study, it is understood that the Investigator is obliged to provide the Sponsor with complete test results, all study data, and access to all study records.  
The Sponsor recognizes the importance of communicating study data and will disclose or publish the results in a suitable form regardless of outcome. The Sponsor will publish the results of this 
study in scie ntific journals, at seminars or conferences, and/or in other manner(s) it so chooses. 
Results from this study shall not be made available to any third party by [CONTACT_596845]. 
11. BENEFIT/RISK ASSESSMENT 
11.1. Non-Clinical Evaluation  
Single -dose and repeat -dose toxicology, safety pharmacology, and genotoxicity studies have 
been conducted with avacopan. General toxic ity studies of up to 26-week duration in rats and 44-
week duration in cynomolgus monkeys have been conducted at avacopan doses up to 200 and 45 mg/kg/day, respectively , significantly  higher than the highest human daily dose of 30 mg twice 
daily ( b.i.d.) being tested in this clinical trial and other indications. 
Based on in vivo safety pharmacology studies, which included neuropharmacology, pulmonary, and renal safety studies in rats, and a cardiovascular safety study in conscious telemetered cynomolgus monkeys, there was no evidence of toxicity of avacopan. No evidence of 
electrocardiographic alterations was seen in the monkey 4-week, 20-week, or 44-week studies or 
in in vitro cardiovascular safety studies (IC
50 values for hERG inhibition was determined to be 
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 83 of 87 >2.3 µM for avacopan and >3.0 µM for its metabolite CCX168- M1, the limit of solubility for 
both compounds).  A safety margin for  avacopan  and metabolite CCX168-M1 of at least 3,500 
fold relative to expected steady state human unbound maximum plasma is projected. 
Genotoxicity studies, including in vitro bacterial mutagenicity (Ames test) and in vitro 
mam malian cell mutagenicity (mouse lymphoma) studies, in vivo bone marrow rat micronucleus 
and in silico mutagenicity evaluation of starting materials, intermediates and chemical impurities 
utilized and formed during the synthesis of avacopan were also conducted and did not identify 
any safety concerns or significant potential for drug-drug interactions. In an acute toxicology 
study, single doses of avacopan up to 100 mg/kg in rats produced no remarkable effects. No effects on IgG and IgM antibody production in rats or monkeys were noted following 
immunization with keyhole limpet hemocyanin antigen. Immunophenotypic analyses performed 
in the 44-week monkey study did not reveal any avacopan-related effects. No phototoxicity potential was observed for avacopan in the in vitro 3T3 assay. 
Avacopan was well tolerated in studies up to [ADDRESS_788438] doses tested (200 mg/kg/day in rats and 45 mg/kg/day in 
cynomolgus monkeys). These doses provide an exposure margin of ~19-fold and ~6-fold, 
respectively, compared to the projected avacopan steady -state exposure with the 30 mg twice 
daily therapeutic dose in humans. There were no significant toxicological findings of concern in 
these chronic studies or the preceding sub-chronic studies. Metabolite CCX168-M1 (which has 
been identified in humans) was present in samples collected in the rat 26-week and the monkey 
44-week studies at relatively high levels indicating that this metabolite has been qualified.  
No avacopan -related effects were observed upon pregnancy or embryo-fetal development in 
studies at doses up to 1000 mg/kg and 200 mg/kg in hamsters and rabbits, respectively. No evidence of histopathological alterations to the male or female reproductive system wa s seen in 
rats or monkeys in toxicology studies. A pre and post- natal  development study (Segment III) in 
hamsters with avacopan given at doses up to 1,000 mg/kg/day (500 mg/kg b.i.d.) from GD 6-12 and through lactation until weaning of the offspring, resulted in no adverse findings in either the F
0 dams or the F 1 offspring, including developmental, behavioral, immunological or reproductive 
measures ( PC0673_168). Analysis of avacopan plasma levels in the lactating dams and the 
plasma levels in nursing offspring showed the presence of avacopan, suggesting avacopan is likely excreted into the milk of lactating hamsters.  
In summary, no safety findings in toxicology studies in rats, cynomolgus monkeys, rabbits and hamsters have been observed that would preclude dosing to humans at the [ADDRESS_788439] been completed at avacopan doses ranging from 1 mg up to 100 mg 
(CL001_168, CL004_168, CL007_168, CL008_168, and CCX1101). Avacopan was generally well tolerated in these studies.  
The most frequently reported adverse events in subjects receiving avacopan in Phase 1 clinical studies were headache (14.6% vs. 14.3% for placebo), diarrhea (6.7% vs. 7.1% for placebo), dizziness ( 4.5% vs. 0% for placebo), upper respi[INVESTIGATOR_1092] (4.5% vs. 0% for placebo), 
nausea (3.4% vs. 0% for placebo), oropharyngeal pain (3.4% vs. 7.1% for placebo), and WBC 
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 84 of 87 count decreased (3.4% vs. 0% for placebo). All other adverse events occurred at an incidence 
less than 3 %. 
In addition, a Phase 1 study in subjects with mild (N=8) or moderate (N=8) hepatic impairment 
(as defined using Child-Pugh [C- P] Classification of the Severity of Liver Disease criteria) 
compared to healthy matched controls (N=8) studying a single dose of [ADDRESS_788440] on avacopan exposure. As a result, no dose adjustment is necessary for subje cts with mild to moderate hepatic impairment.  
An ethno-bridging Phase 1 study (CCX1101) was conducted  in [ADDRESS_788441] the safety and PK of avacopan and its major metabolite CCX168- M1 in the Japanese su bjects compared to 24 Caucasian healthy adult males. 
In addition, two Phase 2 clinical trials (CL002_168 and CL003_168) have been conducted in [ADDRESS_788442] s with AAV; [ADDRESS_788443] s receiving avacopan compared to the 
control group. Vasculitis or renal vasculitis (worsening) was also reported at a similar incidence in the two groups. 
The most commonly rep orted treatment -emergent adverse events in subject s with AAV receiving 
avacopan in studies CL002_168 and CL003_168 combined were hypertension (17.8% vs. 16.7% 
in the control group), nausea (17.8% vs. 19.4% in the control group), vomiting (13.7% vs. 0.0% 
in the control group), headache (11.0% vs. 11.1% in the control group), nasopharyngitis (11.0% 
vs. 8.3% in the control group), peripheral edema (9.6% vs. 11.1% in the control group), 
arthralgia (8.2% vs. 2.8% in the control group), and diarrhea (8.2% vs. 2.8% in the control 
group). Grade [ADDRESS_788444] 2 weeks of treatment, and was not progressive with 
continued treatment.  Avacopan  did not show evidence of pro- arrhythmic potential in an intensive 
ECG study (CL007_168). 
Caution should be exercised when avacopan is given with potent CYP3A4 inhibitors such as 
itraconazole, since the avacopan plasma exposure may increase approximately two -fold. 
Avacopan has shown evidence of efficacy in Phase 2 study CL002_168 based on BVAS, quality 
of life measurements, renal response, urinary albuminuria, and urinary MCP- 1:creatinine results. 
This effic acy was demonstrated across a number of relevant immunological and clinical 
subgroups, i.e., subject s with MPO ANCA-positive disease vs. PR3 ANCA-positive disease, 
newly diagnosed vs. relapsing subject s, subject s on cyclophosphamide vs. those on ri tuximab.   
It is of note that as avacopan is a selective C5aR blocker , it does not appear to affect the 
formation of C5b and the membrane attack complex (MAC) or terminal complement complex (TCC) which is needed to protect against Neisseria  infections. Nevertheless, subjects should 
adhere to all local v accination program requirements, Investigators should be vigilant in 
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 85 of 87 reporting all infections occurring during clinical trials and should attempt to identify the 
organisms involved in all infections. 
In an ongoing Phase 3 study (CL010_168) of  approximately 300 subjects with AAV , subjects 
receive avacopan and background therapy of cyclophosphamide followed by [CONTACT_596806], or in 
combination with rituximab . The control group receives high dose glucocorticoids on 
backgrou nd therapy with cyclophosphamide followed by [CONTACT_596806], or in combination with 
rituximab . The study remains blinded to the Sponsor, Investigators and subjects. An unblinded 
Data Monitoring Committee (DMC) of study CL010_168 recommended notification be sent to 
Investigators with the following observations: (a) urticaria with angioe dema in two  subject s, and 
(b) elevated liver transaminases in several subjects on blinded study drug (with one event of 
biopsy consistent- hepatocellular damage in a subject receiving active study drug in combination 
with immunosuppressive and other drugs), and (c) events of nausea, vomiting, and diarrhea.  
Informed Consent Form(s) were also updated. 
Therefore, the Reference Safety Information section of the Investigator ’s Brochure has been 
updated to include the potential risk of urticaria, angioedema, and of hepatotoxicity, and to state 
that general gastrointestinal adverse events (e.g., nausea, diarrhea) observed in Phase [ADDRESS_788445] with C3 glomerulopathy (CL011_168) and agranulocytosis in the ongoing and blinded 
Phase 3 study of avacopan in subjects with AAV (ADVOCATE, CL010_168). In all reported cases, subjects were receiving multiple immunosuppressants (e.g. , cyclophosphamide, rituximab, 
mycophenolate mofetil, others) in addition to study medication. 
11.3. Summary Benefit -Risk Statement  
Based on the nonclinical and clinical study results, the potential benefits of testing avacopan in subjects with HS outweigh the potential risks. 
Subjects participating in clinical trials must be closely monitored for  any adverse events, and 
laboratory, physical examination, or vital signs abnormalities.  WBC and differential counts, and 
liver enzyme values must be monitored over the course of the studies. 
As with all investigational compounds, the potential exists for unanticipated serious or life-
threatening toxicities or adverse events not predicted by [CONTACT_596846]. Investigators should exercise vigilance in the monitoring of subjects involved in this clinical trial with avacopan . 
For additional details, please refer to the current version of the Investigator’s Brochure.
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 86 of 87 12. REFERENCES  
1. Bekker P, et al. Characterization of pharmacologic and pharmacokinetic properties of 
CCX168, a potent and s elective orally administered complem ent 5a receptor inhibitor, based 
on preclinical evaluation and randomized phase 1 clinical study. PLoS ONE 11: e0164646. 
doi:10.1371/journal.pone.0164646. 
2. Guidance for industry. Drug-induced liver injury: premarketing clinical evaluation. Food and 
drug administration, July 2009. 
http://www.fda.gov/downloads/Drugs/.../Guidances/UCM174090.pdf. 
3. Guo R, et al. IFX-1 blocking the anaphylatoxin C5a – an anti -inflammatory effect in subject s 
with hidradenitis suppurativa. Poster presentation  at the 16th European Meeting on 
Complement in Human Disease (EMCHD2017), Copenhagen, Sep 2017. 
https://www.inflarx.de/dam/jcr:ec982d1e -f82b-4992-a1b0 
ff6e69a04b6b/Guo_2017_poster.pdf 
4. Jayne DRW, et al. Randomized trial of C5a receptor inhibitor avacopan in ANCA- associated 
vasculit is. J Am Soc Nephrol 2017;28:2756-2767. 
5. Johnson TN, et al. Prediction of the clearance of eleven drugs and associated variability in 
neonates, infants and children. Clin Pharmacokinet 2006;45:931-956. 
6. Kanni T, et al. Complement activation in hidradenitis s uppurativa: a new pathway of 
pathogenesis? Br J Dermatol 2018;179:413-419.  
7. Kimball AB, Kerdel F, Adams D, et al. Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med 2012;157:846-855. 
8. Kimball AB, et al. Assessing the validity, responsiveness and meaningfulness of the 
Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment. Br J Dermatol 2014;171:1434-1442.  
9. Kimball AB, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J 
Med 2016a;375:422-434. 
10. Kimball AB, et al. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppur ativa from the 
placebo -controlled portion of a phase 2 adalimumab study. J Eur Acad Dermat ol Venereol 
2016b;30:989-994. 
11. Napolitano M, et al. Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment. Clin Cosmet Investig Dermatol 2017 ;10:105-115. 
12. Prens E and Deckers I. Pathophysiology of hidradenitis suppurativa: An update. J Am Acad 
Dermatol 2015;73:S8-S11. 
13. Radtke F, et al . Notch signaling in the immune system. Immunity 2010;32:14-27.  
14. Sartorius K, et al. Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa. Br J Dermatol 2003;149:211-213. 
Avacopan (CCX168)   Protocol CL016_168 
31 July 2019  Amendment 2.0 
ChemoCentryx, Inc.  CONFIDENTIAL  Page 87 of 87 15. Sartorius K, et al . Objective scoring of hidradenitis suppurativa reflecting the role of tobacco 
smoking and obesity. Br J Dermatol 2009;161:831-839. 
16. Wang B, et al. Gamma -secretase gene mutations in familial acne inversa. Science. 2010;  
330:1065. 
17. Xiao H, et al. C5a receptor (CD88) blockade protects against MPO- ANCA GN. J Am Soc 
Nephrol 2014;25:225-231. 
18. Zouboulis CC, et al. Hidradenitis suppurativa/acne inversa: criteria for diagnosis, severity 
assessment, classification and disease evaluation. Dermatology 2015;231:184-190. 
19. Zouboulis CC, et al. Development and validation of the International Hidradenitis 
Suppurativa Severity Score System (IHS4),  a novel dynamic s coring system to assess HS 
severity . Br J of Dermatol  2017 Nov;177:1401-1409. 